| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.665 | 0.009 | 0.67 | 5 Hydroxytryptamine release stimulant | 0.67 0.009 DBMET00510 0.637 0.011 DBMET00869 | DBMET00510 | |
| 0.538 | 0.03 | 0.538 | Antiobesity | 0.361 0.082 DBMET00510 0.255 0.152 DBMET00869 | ||
| 0.518 | 0.044 | 0.518 | Analgesic | |||
| 0.442 | 0.013 | 0.442 | Calcium channel activator | 0.4 0.025 DBMET00510 0.397 0.025 DBMET00869 | ||
| 0.394 | 0.002 | 0.394 | Papain-like protease (SARS coronavirus) inhibitor | 0.126 0.069 DBMET00869 | ||
| 0.393 | 0.007 | 0.393 | Nav1.2 sodium channel blocker | 0.19 0.038 DBMET00510 0.154 0.055 DBMET00869 | ||
| 0.34 | 0.002 | 0.34 | Calcium-sensing receptor agonist | 0.051 0.005 DBMET00510 0.034 0.01 DBMET00869 | ||
| 0.319 | 0.005 | 0.319 | Nav1.6 sodium channel blocker | 0.134 0.075 DBMET00510 0.129 0.082 DBMET00869 | ||
| 0.347 | 0.033 | 0.347 | Potassium channel blocker | |||
| 0.395 | 0.085 | 0.524 | Calcium channel L-type activator | 0.519 0.021 DBMET00510 0.524 0.02 DBMET00869 | DBMET00869 | |
| 0.363 | 0.059 | 0.666 | Cholesterol antagonist | 0.642 0.013 DBMET00510 0.666 0.011 DBMET00869 | DBMET00869 | |
| 0.402 | 0.099 | 0.402 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.394 0.106 DBMET00510 0.267 0.26 DBMET00869 | ||
| 0.321 | 0.046 | 0.321 | Antiamyloidogenic | 0.178 0.116 DBMET00510 0.265 0.065 DBMET00869 | ||
| 0.346 | 0.084 | 0.455 | Toll-Like receptor agonist | 0.455 0.042 DBMET00510 0.366 0.074 DBMET00869 | DBMET00510 | |
| 0.343 | 0.085 | 0.449 | Toll-Like receptor 7 agonist | 0.449 0.043 DBMET00510 0.365 0.074 DBMET00869 | DBMET00510 | |
| 0.298 | 0.049 | 0.455 | Hypolipemic | 0.455 0.017 DBMET00510 0.404 0.025 DBMET00869 | DBMET00510 | |
| 0.24 | 0.005 | 0.24 | Sphingomyelinase inhibitor | 0.141 0.029 DBMET00510 0.124 0.038 DBMET00869 | ||
| 0.304 | 0.084 | 0.429 | Vasodilator, coronary | 0.41 0.032 DBMET00510 0.429 0.027 DBMET00869 | DBMET00869 | |
| 0.213 | 0.012 | 0.213 | Vanilloid antagonist | |||
| 0.258 | 0.06 | 0.837 | Tyrosine 3 hydroxylase inhibitor | 0.734 0.002 DBMET00510 0.837 0.002 DBMET00869 | DBMET00869 | |
| 0.333 | 0.136 | 0.728 | Cyclophilin D inhibitor | 0.728 0.011 DBMET00510 0.665 0.018 DBMET00869 | DBMET00510 | |
| 0.214 | 0.02 | 0.214 | Nav1.3 sodium channel blocker | |||
| 0.262 | 0.083 | 0.262 | Ca(v)3.3 blocker | |||
| 0.263 | 0.085 | 0.429 | Insulysin inhibitor | 0.427 0.018 DBMET00510 0.429 0.018 DBMET00869 | DBMET00869 | |
| 0.205 | 0.028 | 0.205 | Calcium channel blocker | |||
| 0.229 | 0.052 | 0.428 | Neurotrophic factor enhancer | 0.33 0.012 DBMET00510 0.428 0.005 DBMET00869 | DBMET00869 | |
| 0.262 | 0.086 | 0.402 | Spasmolytic | 0.36 0.05 DBMET00510 0.402 0.04 DBMET00869 | DBMET00869 | |
| 0.166 | 0.004 | 0.166 | Sphingosine 1-phosphate receptor 1 antagonist | 0.122 0.005 DBMET00510 0.109 0.008 DBMET00869 | ||
| 0.164 | 0.005 | 0.164 | Neurokinin antagonist | |||
| 0.243 | 0.087 | 0.532 | 5 Hydroxytryptamine uptake stimulant | 0.531 0.004 DBMET00510 0.532 0.004 DBMET00869 | DBMET00869 | |
| 0.173 | 0.017 | 0.173 | Calcium antagonist | 0.112 0.04 DBMET00510 | ||
| 0.16 | 0.005 | 0.16 | Sphingosine 1-phosphate receptor antagonist | 0.132 0.009 DBMET00510 0.122 0.012 DBMET00869 | ||
| 0.22 | 0.07 | 0.273 | Anticonvulsant | 0.273 0.048 DBMET00510 0.144 0.137 DBMET00869 | DBMET00510 | |
| 0.168 | 0.02 | 0.168 | Nav1.5 sodium channel blocker | |||
| 0.154 | 0.011 | 0.154 | Epoxide hydrolase inhibitor | 0.092 0.031 DBMET00510 0.067 0.057 DBMET00869 | ||
| 0.15 | 0.012 | 0.15 | Glutamate (mGluR7) agonist | 0.15 0.012 DBMET00510 0.121 0.029 DBMET00869 | ||
| 0.142 | 0.005 | 0.142 | Neurokinin 1 antagonist | |||
| 0.151 | 0.014 | 0.151 | Vanilloid 1 antagonist | |||
| 0.23 | 0.096 | 0.23 | Cardiotonic | 0.221 0.102 DBMET00510 0.163 0.16 DBMET00869 | ||
| 0.189 | 0.058 | 0.189 | 3C-like protease (Human coronavirus) inhibitor | 0.147 0.105 DBMET00510 | ||
| 0.162 | 0.033 | 0.162 | Beta amyloid protein antagonist | 0.109 0.078 DBMET00510 0.097 0.093 DBMET00869 | ||
| 0.158 | 0.03 | 0.158 | Calcium channel (voltage-sensitive) blocker | |||
| 0.139 | 0.018 | 0.167 | Adrenaline agonist | 0.118 0.026 DBMET00510 0.167 0.011 DBMET00869 | DBMET00869 | |
| 0.154 | 0.036 | 0.211 | Sphingosine 1-phosphate receptor 2 antagonist | 0.211 0.005 DBMET00510 0.202 0.007 DBMET00869 | DBMET00510 | |
| 0.131 | 0.013 | 0.209 | Sphingosine 1-phosphate receptor 4 agonist | 0.209 0.004 DBMET00510 0.179 0.005 DBMET00869 | DBMET00510 | |
| 0.131 | 0.014 | 0.131 | Lipase inhibitor | 0.086 0.037 DBMET00510 0.095 0.03 DBMET00869 | ||
| 0.259 | 0.143 | 0.279 | Calpain 2 inhibitor | 0.279 0.128 DBMET00510 0.248 0.151 DBMET00869 | DBMET00510 | |
| 0.135 | 0.02 | 0.135 | Potassium channel (Voltage-sensitive) activator | |||
| 0.118 | 0.004 | 0.118 | Glucagon receptor antagonist | 0.065 0.007 DBMET00510 0.058 0.008 DBMET00869 | ||
| 0.123 | 0.009 | 0.155 | Peroxisome proliferator-activated receptor gamma antagonist | 0.155 0.005 DBMET00510 0.149 0.006 DBMET00869 | DBMET00510 | |
| 0.118 | 0.005 | 0.118 | Substance P antagonist | |||
| 0.122 | 0.01 | 0.122 | Calcium channel T-type blocker | |||
| 0.155 | 0.043 | 0.21 | Cathepsin H inhibitor | 0.21 0.02 DBMET00510 0.172 0.033 DBMET00869 | DBMET00510 | |
| 0.118 | 0.01 | 0.155 | NMDA 2A receptor antagonist | 0.138 0.008 DBMET00510 0.155 0.007 DBMET00869 | DBMET00869 | |
| 0.161 | 0.054 | 0.161 | Cytokine production inhibitor | 0.12 0.089 DBMET00510 | ||
| 0.112 | 0.005 | 0.112 | TRPM8 blocker | |||
| 0.209 | 0.106 | 0.249 | Calpain inhibitor | 0.249 0.066 DBMET00510 0.233 0.081 DBMET00869 | DBMET00510 | |
| 0.126 | 0.023 | 0.126 | Rho-associated kinase II inhibitor | |||
| 0.155 | 0.053 | 0.235 | Sphingosine 1-phosphate receptor 5 antagonist | 0.235 0.004 DBMET00510 0.222 0.005 DBMET00869 | DBMET00510 | |
| 0.121 | 0.021 | 0.121 | Cannabinoid receptor antagonist | |||
| 0.137 | 0.038 | 0.137 | Chemokine receptor antagonist | |||
| 0.117 | 0.021 | 0.117 | CXC chemokine 4 receptor antagonist | |||
| 0.205 | 0.111 | 0.226 | Neuropeptide Y2 antagonist | 0.226 0.081 DBMET00510 0.22 0.088 DBMET00869 | DBMET00510 | |
| 0.121 | 0.03 | 0.152 | Lanosterol 14 alpha demethylase inhibitor | 0.152 0.01 DBMET00510 0.131 0.021 DBMET00869 | DBMET00510 | |
| 0.124 | 0.034 | 0.264 | NMDA receptor antagonist | 0.216 0.012 DBMET00510 0.264 0.008 DBMET00869 | DBMET00869 | |
| 0.125 | 0.035 | 0.125 | Nitric-oxide synthase inhibitor | 0.106 0.051 DBMET00510 | ||
| 0.102 | 0.016 | 0.102 | Cannabinoid CB1 receptor antagonist | |||
| 0.179 | 0.093 | 0.453 | Psychostimulant | 0.453 0.015 DBMET00510 0.445 0.016 DBMET00869 | DBMET00510 | |
| 0.096 | 0.011 | 0.096 | Potassium channel (Tandem pore domain) blocker | |||
| 0.089 | 0.005 | 0.089 | Acetyl-CoA carboxylase inhibitor | |||
| 0.109 | 0.026 | 0.109 | Myeloperoxidase inhibitor | 0.094 0.043 DBMET00510 0.106 0.029 DBMET00869 | ||
| 0.087 | 0.006 | 0.087 | Beta 2 adrenoreceptor agonist | 0.072 0.016 DBMET00510 0.085 0.007 DBMET00869 | ||
| 0.131 | 0.051 | 0.131 | Calcium channel N-type blocker | |||
| 0.089 | 0.008 | 0.094 | DNA helicase inhibitor | 0.094 0.007 DBMET00510 0.082 0.01 DBMET00869 | DBMET00510 | |
| 0.108 | 0.028 | 0.147 | NMDA 2 receptor antagonist | 0.111 0.027 DBMET00510 0.147 0.017 DBMET00869 | DBMET00869 | |
| 0.095 | 0.016 | 0.118 | Beta 3 adrenoreceptor antagonist | 0.088 0.019 DBMET00510 0.118 0.01 DBMET00869 | DBMET00869 | |
| 0.132 | 0.053 | 0.244 | Sphingosine 1-phosphate receptor 4 antagonist | 0.244 0.005 DBMET00510 0.206 0.008 DBMET00869 | DBMET00510 | |
| 0.148 | 0.071 | 0.21 | Thiol protease inhibitor | 0.21 0.036 DBMET00510 0.174 0.052 DBMET00869 | DBMET00510 | |
| 0.09 | 0.015 | 0.168 | Glycine transporter 2 inhibitor | 0.112 0.011 DBMET00510 0.168 0.007 DBMET00869 | DBMET00869 | |
| 0.084 | 0.01 | 0.084 | Kinesin antagonist | |||
| 0.084 | 0.01 | 0.084 | Kinesin-like protein 1 inhibitor | |||
| 0.079 | 0.006 | 0.079 | Immunoglobulin Fc receptor antagonist | 0.076 0.008 DBMET00510 0.064 0.017 DBMET00869 | ||
| 0.135 | 0.064 | 0.28 | Toll-Like receptor 2 antagonist | 0.231 0.013 DBMET00510 0.28 0.006 DBMET00869 | DBMET00869 | |
| 0.182 | 0.112 | 0.182 | ErbB-1 antagonist | |||
| 0.137 | 0.068 | 0.137 | Sodium channel blocker | |||
| 0.079 | 0.009 | 0.079 | Neurokinin 3 antagonist | |||
| 0.195 | 0.126 | 0.428 | Interleukin agonist | 0.428 0.015 DBMET00510 0.418 0.016 DBMET00869 | DBMET00510 | |
| 0.082 | 0.015 | 0.115 | Sphingosine 1-phosphate receptor 3 antagonist | 0.115 0.005 DBMET00510 0.107 0.006 DBMET00869 | DBMET00510 | |
| 0.079 | 0.013 | 0.079 | Epithelial sodium channel blocker | 0.078 0.013 DBMET00510 0.072 0.017 DBMET00869 | ||
| 0.147 | 0.081 | 0.193 | CF transmembrane conductance regulator agonist | 0.171 0.045 DBMET00510 0.193 0.026 DBMET00869 | DBMET00869 | |
| 0.094 | 0.028 | 0.094 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.082 | 0.016 | 0.082 | Potassium channel intermediate-conductance Ca-activated blocker | 0.059 0.044 DBMET00510 | ||
| 0.107 | 0.042 | 0.107 | Potassium channel activator | |||
| 0.08 | 0.016 | 0.084 | Sphingosine kinase inhibitor | 0.082 0.015 DBMET00510 0.084 0.013 DBMET00869 | DBMET00869 | |
| 0.099 | 0.038 | 0.099 | Inducible nitric-oxide synthase inhibitor | 0.096 0.041 DBMET00510 0.079 0.064 DBMET00869 | ||
| 0.135 | 0.074 | 0.201 | Neurotrophic factor | 0.201 0.027 DBMET00510 0.187 0.034 DBMET00869 | DBMET00510 | |
| 0.065 | 0.005 | 0.065 | Delayed rectifier potassium channel blocker | |||
| 0.072 | 0.012 | 0.079 | Pregnane X receptor antagonist | 0.079 0.007 DBMET00510 0.073 0.011 DBMET00869 | DBMET00510 | |
| 0.064 | 0.005 | 0.064 | GHS receptor antagonist | |||
| 0.069 | 0.014 | 0.069 | Cathepsin L2 inhibitor | |||
| 0.085 | 0.03 | 0.085 | Secretase beta inhibitor | |||
| 0.09 | 0.036 | 0.103 | CC chemokine 5 receptor agonist | 0.099 0.023 DBMET00510 0.103 0.019 DBMET00869 | DBMET00869 | |
| 0.063 | 0.009 | 0.063 | Parathyroid hormone antagonist | |||
| 0.065 | 0.011 | 0.065 | GHS receptor agonist | |||
| 0.063 | 0.009 | 0.063 | Delayed rectifier potassium channel activator | |||
| 0.063 | 0.009 | 0.063 | Potassium channel KCNQ activator | |||
| 0.126 | 0.074 | 0.244 | Vanilloid 1 agonist | 0.207 0.01 DBMET00510 0.244 0.005 DBMET00869 | DBMET00869 | |
| 0.065 | 0.014 | 0.065 | Adenylate cyclase 1 inhibitor | 0.064 0.015 DBMET00510 0.055 0.022 DBMET00869 | ||
| 0.058 | 0.007 | 0.141 | Prostaglandin EP4 antagonist | 0.141 0.004 DBMET00510 0.098 0.004 DBMET00869 | DBMET00510 | |
| 0.17 | 0.121 | 0.17 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.078 | 0.029 | 0.123 | Beta adrenoreceptor antagonist | 0.098 0.017 DBMET00510 0.123 0.009 DBMET00869 | DBMET00869 | |
| 0.054 | 0.005 | 0.054 | Acetyl-CoA carboxylase 2 inhibitor | |||
| 0.058 | 0.01 | 0.058 | Histamine H1 receptor agonist | 0.041 0.038 DBMET00510 | ||
| 0.052 | 0.004 | 0.052 | Microsomal triglyceride transfer protein inhibitor | |||
| 0.061 | 0.015 | 0.061 | CC chemokine 4 receptor antagonist | |||
| 0.083 | 0.037 | 0.083 | Calcium channel L-type blocker | |||
| 0.073 | 0.028 | 0.073 | Cathepsin L inhibitor | |||
| 0.062 | 0.019 | 0.062 | CC chemokine 3 receptor antagonist | |||
| 0.095 | 0.052 | 0.095 | Ca(v)2.2 blocker | |||
| 0.077 | 0.034 | 0.077 | Histone deacetylase inhibitor | |||
| 0.105 | 0.062 | 0.111 | Protease inhibitor | 0.111 0.055 DBMET00510 0.085 0.08 DBMET00869 | DBMET00510 | |
| 0.104 | 0.062 | 0.106 | Nav1.1 sodium channel blocker | 0.101 0.065 DBMET00510 0.106 0.06 DBMET00869 | DBMET00869 | |
| 0.054 | 0.012 | 0.066 | Beta adrenoreceptor agonist | 0.052 0.014 DBMET00510 0.066 0.006 DBMET00869 | DBMET00869 | |
| 0.054 | 0.013 | 0.054 | Sphingosine kinase 1 inhibitor | 0.053 0.014 DBMET00510 0.048 0.018 DBMET00869 | ||
| 0.059 | 0.019 | 0.059 | Neurokinin 2 antagonist | |||
| 0.047 | 0.007 | 0.047 | Methionyl aminopeptidase 1 inhibitor | 0.044 0.009 DBMET00510 | ||
| 0.199 | 0.159 | 0.199 | Nootropic | |||
| 0.076 | 0.038 | 0.076 | Potassium channel large-conductance Ca-activated activator | 0.064 0.053 DBMET00869 | ||
| 0.072 | 0.034 | 0.097 | Protease 3C (Human rhinovirus) inhibitor | 0.097 0.017 DBMET00510 0.084 0.024 DBMET00869 | DBMET00510 | |
| 0.106 | 0.068 | 0.166 | Nav1.4 sodium channel blocker | 0.164 0.029 DBMET00510 0.166 0.028 DBMET00869 | DBMET00869 | |
| 0.046 | 0.008 | 0.07 | Tryptophan 5 hydroxylase inhibitor | 0.07 0.003 DBMET00510 0.05 0.005 DBMET00869 | DBMET00510 | |
| 0.077 | 0.041 | 0.077 | CXC chemokine receptor antagonist | |||
| 0.095 | 0.059 | 0.129 | Potassium channel (Ca-activated) activator | 0.117 0.043 DBMET00510 0.129 0.036 DBMET00869 | DBMET00869 | |
| 0.146 | 0.111 | 0.265 | Neurotensin receptor agonist | 0.242 0.022 DBMET00510 0.265 0.019 DBMET00869 | DBMET00869 | |
| 0.044 | 0.009 | 0.044 | Vanilloid 4 antagonist | |||
| 0.123 | 0.088 | 0.139 | Histone deacetylase SIRT1 inhibitor | 0.118 0.094 DBMET00510 0.139 0.071 DBMET00869 | DBMET00869 | |
| 0.057 | 0.023 | 0.057 | Melanocortin antagonist | |||
| 0.046 | 0.013 | 0.046 | Potassium channel subfamily K member 3 blocker | |||
| 0.072 | 0.038 | 0.087 | Exportin-1 inhibitor | 0.087 0.018 DBMET00510 0.07 0.044 DBMET00869 | DBMET00510 | |
| 0.093 | 0.06 | 0.161 | ABCA1 expression enhancer | 0.161 0.015 DBMET00510 0.136 0.022 DBMET00869 | DBMET00510 | |
| 0.052 | 0.019 | 0.052 | Cathepsin L1 inhibitor | |||
| 0.05 | 0.017 | 0.05 | Growth hormone secretagogue receptor antagonist | |||
| 0.043 | 0.011 | 0.075 | Lysophosphatidic acid 2 receptor antagonist | 0.075 0.005 DBMET00510 0.049 0.009 DBMET00869 | DBMET00510 | |
| 0.037 | 0.005 | 0.037 | Acid ceramidase inhibitor | 0.03 0.009 DBMET00510 | ||
| 0.058 | 0.026 | 0.058 | Glycine transporter inhibitor | |||
| 0.08 | 0.049 | 0.08 | Viral attachment inhibitor | |||
| 0.057 | 0.026 | 0.107 | Lysophosphatidic acid 3 receptor antagonist | 0.107 0.004 DBMET00510 0.087 0.007 DBMET00869 | DBMET00510 | |
| 0.061 | 0.03 | 0.084 | Sphingosine kinase 2 inhibitor | 0.081 0.015 DBMET00510 0.084 0.013 DBMET00869 | DBMET00869 | |
| 0.036 | 0.006 | 0.036 | Protease (Human cytomegalovirus) inhibitor | |||
| 0.067 | 0.037 | 0.067 | Cannabinoid CB1 receptor agonist | |||
| 0.082 | 0.054 | 0.082 | Ca(v)3.1 blocker | |||
| 0.077 | 0.049 | 0.077 | Protein kinase B gamma inhibitor | |||
| 0.099 | 0.071 | 0.118 | Factor V inhibitor | 0.118 0.041 DBMET00510 0.1 0.069 DBMET00869 | DBMET00510 | |
| 0.049 | 0.021 | 0.055 | GABA B receptor antagonist | 0.055 0.015 DBMET00510 0.041 0.033 DBMET00869 | DBMET00510 | |
| 0.051 | 0.023 | 0.051 | Melanocortin 4 antagonist | |||
| 0.129 | 0.101 | 0.138 | Neuropeptide Y1 antagonist | 0.132 0.097 DBMET00510 0.138 0.085 DBMET00869 | DBMET00869 | |
| 0.264 | 0.236 | 0.651 | Caspase 9 stimulant | 0.541 0.047 DBMET00510 0.651 0.03 DBMET00869 | DBMET00869 | |
| 0.087 | 0.059 | 0.19 | Ornithine decarboxylase inhibitor | 0.19 0.005 DBMET00510 0.183 0.005 DBMET00869 | DBMET00510 | |
| 0.057 | 0.03 | 0.181 | Prostaglandin E2 antagonist | 0.181 0.006 DBMET00510 0.093 0.016 DBMET00869 | DBMET00510 | |
| 0.039 | 0.012 | 0.039 | Bradykinin B1 receptor antagonist | |||
| 0.079 | 0.053 | 0.079 | CC chemokine receptor antagonist | |||
| 0.044 | 0.019 | 0.05 | Diamine oxidase inhibitor | 0.05 0.014 DBMET00510 0.033 0.032 DBMET00869 | DBMET00510 | |
| 0.21 | 0.186 | 0.437 | Immunosuppressant | 0.437 0.051 DBMET00510 0.393 0.066 DBMET00869 | DBMET00510 | |
| 0.075 | 0.051 | 0.075 | Rho-associated kinase inhibitor | |||
| 0.04 | 0.017 | 0.04 | Ceramide glucosyltransferase inhibitor | 0.04 0.018 DBMET00510 0.033 0.031 DBMET00869 | ||
| 0.031 | 0.008 | 0.031 | Apolipoprotein B inhibitor | |||
| 0.072 | 0.05 | 0.271 | Aminopeptidase I inhibitor | 0.271 0.004 DBMET00510 0.22 0.005 DBMET00869 | DBMET00510 | |
| 0.031 | 0.01 | 0.052 | Lysophosphatidic acid receptor 1 agonist | 0.052 0.004 DBMET00510 0.03 0.011 DBMET00869 | DBMET00510 | |
| 0.033 | 0.012 | 0.033 | Methionyl aminopeptidase 2 inhibitor | |||
| 0.056 | 0.036 | 0.056 | CC chemokine 2 receptor antagonist | |||
| 0.043 | 0.022 | 0.043 | Histone deacetylase 9 inhibitor | 0.036 0.033 DBMET00510 | ||
| 0.054 | 0.034 | 0.054 | Cannabinoid CB2 receptor antagonist | |||
| 0.194 | 0.174 | 0.502 | Transcription factor NF kappa B inhibitor | 0.384 0.067 DBMET00510 0.502 0.044 DBMET00869 | DBMET00869 | |
| 0.06 | 0.041 | 0.06 | Potassium channel (Ca-activated) blocker | |||
| 0.031 | 0.011 | 0.031 | Glucosylceramidase stimulant | |||
| 0.036 | 0.017 | 0.036 | Cholesterol ester transfer protein antagonist | 0.03 0.024 DBMET00510 | ||
| 0.249 | 0.23 | 0.623 | 5 Hydroxytryptamine release inhibitor | 0.623 0.008 DBMET00510 0.619 0.009 DBMET00869 | DBMET00510 | |
| 0.151 | 0.132 | 0.392 | Insulin sensitizer | 0.36 0.009 DBMET00510 0.392 0.007 DBMET00869 | DBMET00869 | |
| 0.134 | 0.116 | 0.186 | Antipruritic | 0.186 0.059 DBMET00510 0.171 0.073 DBMET00869 | DBMET00510 | |
| 0.034 | 0.016 | 0.086 | Liver X receptor beta antagonist | 0.074 0.004 DBMET00510 0.086 0.004 DBMET00869 | DBMET00869 | |
| 0.044 | 0.026 | 0.124 | Sphingosine 1-phosphate receptor 1 agonist | 0.124 0.004 DBMET00510 0.087 0.005 DBMET00869 | DBMET00510 | |
| 0.054 | 0.036 | 0.343 | Sphingosine 1-phosphate receptor 5 agonist | 0.343 0.003 DBMET00510 0.193 0.004 DBMET00869 | DBMET00510 | |
| 0.058 | 0.04 | 0.058 | Dopamine uptake inhibitor | |||
| 0.06 | 0.043 | 0.06 | TRPA1 antagonist | |||
| 0.171 | 0.154 | 0.59 | Superoxide dismutase inhibitor | 0.497 0.013 DBMET00510 0.59 0.007 DBMET00869 | DBMET00869 | |
| 0.055 | 0.038 | 0.057 | Human rhinovirus A protease inhibitor | 0.057 0.037 DBMET00510 | DBMET00510 | |
| 0.04 | 0.023 | 0.04 | Histone deacetylase 7 inhibitor | 0.037 0.026 DBMET00510 | ||
| 0.072 | 0.056 | 0.093 | CYP2A6 inhibitor | 0.093 0.039 DBMET00510 | DBMET00510 | |
| 0.045 | 0.029 | 0.142 | Sphingosine 1-phosphate receptor agonist | 0.142 0.004 DBMET00510 0.101 0.005 DBMET00869 | DBMET00510 | |
| 0.038 | 0.024 | 0.038 | Bradykinin antagonist | |||
| 0.097 | 0.083 | 0.23 | GABA C receptor antagonist | 0.23 0.008 DBMET00510 0.18 0.018 DBMET00869 | DBMET00510 | |
| 0.036 | 0.023 | 0.036 | Gonadotropin-releasing hormone receptor antagonist | |||
| 0.022 | 0.009 | 0.022 | Apolipoprotein B-100 inhibitor | |||
| 0.034 | 0.021 | 0.038 | Melatonin receptor 1A agonist | 0.038 0.016 DBMET00510 | DBMET00510 | |
| 0.08 | 0.067 | 0.182 | Estrogen-related receptor beta agonist | 0.14 0.005 DBMET00510 0.182 0.003 DBMET00869 | DBMET00869 | |
| 0.038 | 0.026 | 0.038 | Potassium channel Kv1.1 blocker | |||
| 0.123 | 0.112 | 0.38 | Phospholipase A2 inhibitor | 0.363 0.007 DBMET00510 0.38 0.005 DBMET00869 | DBMET00869 | |
| 0.034 | 0.022 | 0.299 | Peroxisome proliferator-activated receptor delta antagonist | 0.299 0.003 DBMET00510 0.234 0.004 DBMET00869 | DBMET00510 | |
| 0.08 | 0.069 | 0.167 | Vanilloid agonist | 0.126 0.016 DBMET00510 0.167 0.009 DBMET00869 | DBMET00869 | |
| 0.058 | 0.048 | 0.143 | NMDA 2C receptor antagonist | 0.137 0.008 DBMET00510 0.143 0.007 DBMET00869 | DBMET00869 | |
| 0.04 | 0.03 | 0.112 | Liver X receptor alpha agonist | 0.084 0.006 DBMET00510 0.112 0.005 DBMET00869 | DBMET00869 | |
| 0.039 | 0.03 | 0.039 | Phenylethanolamine N methyltransferase inhibitor | |||
| 0.064 | 0.055 | 0.086 | Elastase 1 inhibitor | 0.086 0.029 DBMET00510 0.081 0.035 DBMET00869 | DBMET00510 | |
| 0.036 | 0.028 | 0.036 | Melanocortin 1 antagonist | |||
| 0.032 | 0.024 | 0.032 | Dipeptidyl peptidase II inhibitor | 0.03 0.026 DBMET00510 | ||
| 0.056 | 0.049 | 0.056 | Adrenaline uptake inhibitor | |||
| 0.032 | 0.025 | 0.133 | Peroxisome proliferator-activated receptor delta agonist | 0.133 0.004 DBMET00510 0.112 0.005 DBMET00869 | DBMET00510 | |
| 0.023 | 0.016 | 0.032 | Beta 1 adrenoreceptor agonist | 0.023 0.014 DBMET00510 0.032 0.007 DBMET00869 | DBMET00869 | |
| 0.028 | 0.022 | 0.028 | Complement C5a chemotactic receptor antagonist | |||
| 0.129 | 0.124 | 0.186 | Ca2+-transporting ATPase inhibitor | 0.186 0.005 DBMET00510 0.173 0.01 DBMET00869 | DBMET00510 | |
| 0.049 | 0.044 | 0.071 | Vanilloid 2 antagonist | 0.056 0.028 DBMET00510 0.071 0.014 DBMET00869 | DBMET00869 | |
| 0.015 | 0.01 | 0.066 | Calcium-sensing receptor antagonist | 0.066 0.005 DBMET00510 0.035 0.005 DBMET00869 | DBMET00510 | |
| 0.018 | 0.014 | 0.018 | Alpha 2b adrenoreceptor agonist | |||
| 0.055 | 0.051 | 0.055 | Ca(v)3.2 blocker | |||
| 0.03 | 0.027 | 0.03 | Melatonin agonist | |||
| 0.042 | 0.04 | 0.164 | Peroxisome proliferator-activated receptor alpha agonist | 0.164 0.005 DBMET00510 0.154 0.006 DBMET00869 | DBMET00510 | |
| 0.039 | 0.037 | 0.048 | Histamine H2 receptor agonist | 0.048 0.024 DBMET00510 | DBMET00510 | |
| 0.033 | 0.032 | 0.033 | Somatostatin 4 agonist | |||
| 0.056 | 0.056 | 0.095 | Neutrophil collagenase inhibitor | 0.095 0.024 DBMET00510 0.081 0.031 DBMET00869 | DBMET00510 | |
| 0.048 | 0.048 | 0.063 | Nicotinic alpha3beta2 receptor antagonist | 0.063 0.023 DBMET00510 | DBMET00510 | |
| 0.08 | 0.08 | 0.429 | Alcohol dehydrogenase inhibitor | 0.386 0.004 DBMET00510 0.429 0.004 DBMET00869 | DBMET00869 | |
| 0.026 | 0.026 | 0.042 | Liver X receptor alpha antagonist | 0.038 0.01 DBMET00510 0.042 0.008 DBMET00869 | DBMET00869 | |
| 0.094 | 0.095 | 0.163 | Proteasome inhibitor | 0.163 0.039 DBMET00510 0.161 0.04 DBMET00869 | DBMET00510 | |
| 0.032 | 0.033 | 0.046 | Calcium-independent phospholipase A2 inhibitor | 0.046 0.005 DBMET00510 0.04 0.01 DBMET00869 | DBMET00510 | |
| 0.023 | 0.025 | 0.044 | Urotensin II agonist | 0.044 0.008 DBMET00510 0.036 0.011 DBMET00869 | DBMET00510 | |
| 0.122 | 0.124 | 0.148 | Pregnane X receptor agonist | 0.148 0.056 DBMET00510 0.136 0.084 DBMET00869 | DBMET00510 | |
| 0.038 | 0.041 | 0.043 | Liver X receptor agonist | 0.043 0.03 DBMET00510 0.042 0.032 DBMET00869 | DBMET00510 | |
| 0.024 | 0.028 | 0.025 | Thrombin receptor antagonist | 0.025 0.024 DBMET00510 | DBMET00510 | |
| 0.188 | 0.193 | 0.553 | Antithrombotic | 0.553 0.022 DBMET00510 0.552 0.022 DBMET00869 | DBMET00510 | |
| 0.162 | 0.166 | 0.187 | 5 Hydroxytryptamine 3E antagonist | 0.187 0.089 DBMET00510 | DBMET00510 | |
| 0.036 | 0.042 | 0.21 | NMDA receptor subunit 3B antagonist | 0.184 0.005 DBMET00510 0.21 0.004 DBMET00869 | DBMET00869 | |
| 0.12 | 0.126 | 0.252 | Adenylate cyclase stimulant | 0.233 0.005 DBMET00510 0.252 0.004 DBMET00869 | DBMET00869 | |
| 0.067 | 0.074 | 0.108 | Vanilloid 4 agonist | 0.108 0.012 DBMET00510 0.086 0.032 DBMET00869 | DBMET00510 | |
| 0.017 | 0.025 | 0.023 | Geranylgeranyltransferase inhibitor | 0.023 0.015 DBMET00510 | DBMET00510 | |
| 0.024 | 0.033 | 0.042 | Liver X receptor antagonist | 0.038 0.015 DBMET00510 0.042 0.013 DBMET00869 | DBMET00869 | |
| 0.009 | 0.018 | 0.126 | Prostaglandin EP4 agonist | 0.126 0.003 DBMET00510 0.112 0.003 DBMET00869 | DBMET00510 | |
| 0.026 | 0.036 | 0.063 | Liver X receptor beta agonist | 0.062 0.008 DBMET00510 0.063 0.008 DBMET00869 | DBMET00869 | |
| 0.127 | 0.137 | 0.216 | Heat shock protein 70 antagonist | 0.2 0.006 DBMET00510 0.216 0.005 DBMET00869 | DBMET00869 | |
| 0.047 | 0.057 | 0.051 | Glucosylceramidase inhibitor | 0.051 0.046 DBMET00510 | DBMET00510 | |
| 0.021 | 0.032 | 0.22 | Prostaglandin EP3 antagonist | 0.22 0.004 DBMET00510 0.133 0.005 DBMET00869 | DBMET00510 | |
| 0.036 | 0.047 | 0.074 | Geranyltranstransferase inhibitor | 0.074 0.006 DBMET00510 0.058 0.015 DBMET00869 | DBMET00510 | |
| 0.048 | 0.059 | 0.129 | Carbonic anhydrase stimulant | 0.129 0.013 DBMET00510 0.096 0.019 DBMET00869 | DBMET00510 | |
| 0.04 | 0.052 | 0.102 | Beta 2 adrenoreceptor antagonist | 0.078 0.013 DBMET00510 0.102 0.008 DBMET00869 | DBMET00869 | |
| 0.014 | 0.027 | 0.022 | Tryptophan hydroxylase 1 inhibitor | 0.022 0.005 DBMET00510 0.017 0.014 DBMET00869 | DBMET00510 | |
| 0.111 | 0.124 | 0.258 | Anticoagulant | 0.258 0.037 DBMET00510 0.18 0.061 DBMET00869 | DBMET00510 | |
| 0.056 | 0.07 | 0.121 | Prostaglandin-E synthase inhibitor | 0.121 0.019 DBMET00510 0.108 0.023 DBMET00869 | DBMET00510 | |
| 0.115 | 0.13 | 0.443 | Growth hormone agonist | 0.443 0.011 DBMET00510 0.402 0.016 DBMET00869 | DBMET00510 | |
| 0.008 | 0.024 | 0.019 | Lysophosphatidic acid receptor 3 agonist | 0.019 0.006 DBMET00510 | DBMET00510 | |
| 0.028 | 0.046 | 0.273 | Glutamate (mGluR3) antagonist | 0.273 0.003 DBMET00510 0.188 0.004 DBMET00869 | DBMET00510 | |
| 0.025 | 0.043 | 0.163 | Free fatty acid receptor 1 antagonist | 0.163 0.002 DBMET00510 0.13 0.002 DBMET00869 | DBMET00510 | |
| 0.033 | 0.053 | 0.05 | Plasmepsin II inhibitor | 0.05 0.018 DBMET00510 0.042 0.028 DBMET00869 | DBMET00510 | |
| 0.039 | 0.06 | 0.084 | Bombesin 2 receptor antagonist | 0.084 0.016 DBMET00510 0.079 0.017 DBMET00869 | DBMET00510 | |
| 0.013 | 0.036 | 0.027 | CXC chemokine 5 receptor antagonist | 0.027 0.005 DBMET00510 | DBMET00510 | |
| 0.013 | 0.037 | 0.037 | Estrogen-related receptor gamma agonist | 0.025 0.005 DBMET00510 0.037 0.003 DBMET00869 | DBMET00869 | |
| 0.033 | 0.057 | 0.047 | Dihydroorotase inhibitor | 0.047 0.028 DBMET00510 | DBMET00510 | |
| 0.02 | 0.045 | 0.034 | Peptide deformylase inhibitor | 0.034 0.018 DBMET00510 | DBMET00510 | |
| 0.039 | 0.064 | 0.051 | HCV NS3/NS4A protease inhibitor | 0.051 0.031 DBMET00510 | DBMET00510 | |
| 0.038 | 0.064 | 0.07 | Aminopeptidase microsomal inhibitor | 0.07 0.031 DBMET00510 0.06 0.04 DBMET00869 | DBMET00510 | |
| 0.014 | 0.04 | 0.103 | Glutamate (mGluR1a) agonist | 0.103 0.004 DBMET00510 0.05 0.005 DBMET00869 | DBMET00510 | |
| 0.021 | 0.047 | 0.042 | Calcitonin receptor agonist | 0.042 0.019 DBMET00510 0.038 0.021 DBMET00869 | DBMET00510 | |
| 0.014 | 0.041 | 0.069 | Lysophosphatidic acid 1 receptor antagonist | 0.069 0.003 DBMET00510 0.046 0.004 DBMET00869 | DBMET00510 | |
| 0.054 | 0.081 | 0.249 | Cathepsin G inhibitor | 0.249 0.012 DBMET00510 0.232 0.014 DBMET00869 | DBMET00510 | |
| 0.068 | 0.096 | 0.286 | Aminopeptidase B inhibitor | 0.286 0.009 DBMET00510 0.25 0.013 DBMET00869 | DBMET00510 | |
| 0.041 | 0.069 | 0.07 | Matrix metalloproteinase (membrane-type) inhibitor | 0.07 0.025 DBMET00510 0.058 0.035 DBMET00869 | DBMET00510 | |
| 0.025 | 0.053 | 0.037 | Growth factor receptor-bound protein 2 antagonist | 0.037 0.02 DBMET00510 0.034 0.027 DBMET00869 | DBMET00510 | |
| 0.021 | 0.049 | 0.032 | Epoxide hydrolase 1 inhibitor | 0.032 0.019 DBMET00510 | DBMET00510 | |
| 0.059 | 0.087 | 0.074 | Somatostatin 1 agonist | 0.074 0.059 DBMET00869 | DBMET00869 | |
| 0.052 | 0.08 | 0.113 | Interferon inducer | 0.113 0.009 DBMET00510 0.084 0.021 DBMET00869 | DBMET00510 | |
| 0.026 | 0.055 | 0.041 | Erythropoietin receptor agonist | 0.04 0.028 DBMET00510 0.041 0.027 DBMET00869 | DBMET00869 | |
| 0.013 | 0.043 | 0.027 | Caspase 8 inhibitor | 0.027 0.006 DBMET00510 0.023 0.009 DBMET00869 | DBMET00510 | |
| 0.025 | 0.054 | 0.052 | Carboxypeptidase B inhibitor | 0.052 0.006 DBMET00510 0.04 0.012 DBMET00869 | DBMET00510 | |
| 0.032 | 0.062 | 0.064 | Metalloproteinase-3 inhibitor | 0.064 0.022 DBMET00510 0.05 0.033 DBMET00869 | DBMET00510 | |
| 0.016 | 0.046 | 0.12 | Sphingosine 1-phosphate receptor 3 agonist | 0.12 0.005 DBMET00510 0.077 0.009 DBMET00869 | DBMET00510 | |
| 0.062 | 0.092 | 0.12 | Chymotrypsin inhibitor | 0.12 0.025 DBMET00510 0.097 0.038 DBMET00869 | DBMET00510 | |
| 0.07 | 0.101 | 0.116 | Urease inhibitor | 0.099 0.068 DBMET00510 0.116 0.049 DBMET00869 | DBMET00869 | |
| 0.033 | 0.064 | 0.39 | Prostaglandin antagonist | 0.39 0.004 DBMET00510 0.197 0.007 DBMET00869 | DBMET00510 | |
| 0.022 | 0.054 | 0.19 | NMDA receptor subunit 3A antagonist | 0.164 0.005 DBMET00510 0.19 0.004 DBMET00869 | DBMET00869 | |
| 0.018 | 0.05 | 0.058 | Sirtuin 2 inhibitor | 0.058 0.01 DBMET00510 0.046 0.014 DBMET00869 | DBMET00510 | |
| 0.046 | 0.079 | 0.241 | NMDA receptor agonist | 0.241 0.004 DBMET00510 0.168 0.006 DBMET00869 | DBMET00510 | |
| 0.02 | 0.053 | 0.027 | Purinergic P2Y15 antagonist | 0.027 0.023 DBMET00510 | DBMET00510 | |
| 0.081 | 0.114 | 0.132 | Histone deacetylase class III inhibitor | 0.109 0.081 DBMET00510 0.132 0.059 DBMET00869 | DBMET00869 | |
| 0.021 | 0.054 | 0.142 | Retinoid X alpha receptor agonist | 0.142 0.003 DBMET00510 0.108 0.005 DBMET00869 | DBMET00510 | |
| 0.006 | 0.04 | 0.182 | G-protein-coupled receptor 120 agonist | 0.182 0.002 DBMET00510 0.109 0.003 DBMET00869 | DBMET00510 | |
| 0.067 | 0.102 | 0.298 | HIV-1 integrase (Overall Integration) inhibitor | 0.29 0.004 DBMET00510 0.298 0.004 DBMET00869 | DBMET00869 | |
| 0.027 | 0.062 | 0.05 | Aminopeptidase N inhibitor | 0.05 0.031 DBMET00510 | DBMET00510 | |
| 0.044 | 0.081 | 0.056 | Cathepsin E inhibitor | 0.056 0.047 DBMET00510 | DBMET00510 | |
| 0.022 | 0.06 | 0.103 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.098 0.004 DBMET00510 0.103 0.004 DBMET00869 | DBMET00869 | |
| 0.056 | 0.094 | 0.095 | Metalloproteinase-9 inhibitor | 0.095 0.035 DBMET00510 0.094 0.035 DBMET00869 | DBMET00510 | |
| 0.024 | 0.064 | 0.057 | Oxytocin agonist | 0.052 0.022 DBMET00510 0.057 0.019 DBMET00869 | DBMET00869 | |
| 0.017 | 0.058 | 0.117 | Kainate receptor 2 antagonist | 0.117 0.004 DBMET00510 0.066 0.01 DBMET00869 | DBMET00510 | |
| 0.033 | 0.075 | 0.057 | Cholesterol esterase inhibitor | 0.057 0.02 DBMET00510 0.049 0.032 DBMET00869 | DBMET00510 | |
| 0.009 | 0.051 | 0.076 | Prostaglandin H2 antagonist | 0.076 0.002 DBMET00510 0.059 0.003 DBMET00869 | DBMET00510 | |
| 0.027 | 0.069 | 0.069 | Glutamate (mGluR8) antagonist | 0.069 0.004 DBMET00510 0.054 0.007 DBMET00869 | DBMET00510 | |
| 0.005 | 0.049 | 0.117 | Peroxisome proliferator-activated receptor alpha antagonist | 0.117 0.004 DBMET00510 0.108 0.004 DBMET00869 | DBMET00510 | |
| 0.013 | 0.057 | 0.028 | Neuraminidase (Influenza B) inhibitor | 0.028 0.005 DBMET00510 0.024 0.01 DBMET00869 | DBMET00510 | |
| 0.013 | 0.057 | 0.08 | Prostaglandin F2 alpha agonist | 0.077 0.002 DBMET00510 0.08 0.002 DBMET00869 | DBMET00869 | |
| 0.055 | 0.098 | 0.121 | Metalloproteinase-2 inhibitor | 0.121 0.029 DBMET00510 0.118 0.03 DBMET00869 | DBMET00510 | |
| 0.029 | 0.073 | 0.046 | Nerve growth factor antagonist | 0.046 0.024 DBMET00510 | DBMET00510 | |
| 0.004 | 0.049 | 0.02 | Angiotensin AT1B receptor antagonist | 0.02 0.006 DBMET00510 | DBMET00510 | |
| 0.037 | 0.081 | 0.053 | Acetylcholine M3 receptor antagonist | 0.053 0.051 DBMET00869 | DBMET00869 | |
| 0.007 | 0.051 | 0.016 | Integrin alphaVbeta6 antagonist | 0.016 0.008 DBMET00510 0.016 0.008 DBMET00869 | DBMET00869 | |
| 0.016 | 0.061 | 0.047 | Vanilloid 2 agonist | 0.047 0.003 DBMET00510 0.047 0.003 DBMET00869 | DBMET00869 | |
| 0.014 | 0.059 | 0.019 | Toll-Like receptor 8 agonist | 0.019 0.018 DBMET00510 | DBMET00510 | |
| 0.033 | 0.079 | 0.37 | Prostaglandin EP2 antagonist | 0.37 0.004 DBMET00510 0.259 0.005 DBMET00869 | DBMET00510 | |
| 0.045 | 0.091 | 0.263 | Catalase inhibitor | 0.263 0.008 DBMET00510 0.226 0.011 DBMET00869 | DBMET00510 | |
| 0.057 | 0.104 | 0.159 | Interferon agonist | 0.159 0.009 DBMET00510 0.111 0.021 DBMET00869 | DBMET00510 | |
| 0.073 | 0.12 | 0.192 | Adenylate cyclase inhibitor | 0.18 0.03 DBMET00510 0.192 0.027 DBMET00869 | DBMET00869 | |
| 0.036 | 0.083 | 0.098 | Glucagon-like peptide 1 agonist | 0.098 0.023 DBMET00510 0.09 0.028 DBMET00869 | DBMET00510 | |
| 0.006 | 0.054 | 0.028 | Calcium-dependent phospholipase A2 inhibitor | 0.028 0.004 DBMET00510 0.018 0.005 DBMET00869 | DBMET00510 | |
| 0.074 | 0.123 | 0.205 | Carbonic anhydrase XV inhibitor | 0.157 0.028 DBMET00510 0.205 0.018 DBMET00869 | DBMET00869 | |
| 0.061 | 0.111 | 0.174 | Glutathione S-transferase inhibitor | 0.169 0.009 DBMET00510 0.174 0.008 DBMET00869 | DBMET00869 | |
| 0.026 | 0.076 | 0.051 | Potassium channel Kv1.3 blocker | 0.051 0.028 DBMET00510 0.049 0.03 DBMET00869 | DBMET00510 | |
| 0.04 | 0.089 | 0.325 | Peroxisome proliferator-activated receptor gamma agonist | 0.325 0.004 DBMET00510 0.241 0.005 DBMET00869 | DBMET00510 | |
| 0.073 | 0.123 | 0.134 | Glutamate release inhibitor | 0.134 0.015 DBMET00510 0.112 0.028 DBMET00869 | DBMET00510 | |
| 0.003 | 0.054 | 0.012 | Carboxypeptidase B2 inhibitor | 0.012 0.007 DBMET00510 | DBMET00510 | |
| 0.024 | 0.076 | 0.072 | Oleamide hydrolase inhibitor | 0.072 0.015 DBMET00510 0.069 0.016 DBMET00869 | DBMET00510 | |
| 0.009 | 0.061 | 0.135 | Prostaglandin E2 agonist | 0.135 0.003 DBMET00510 0.124 0.004 DBMET00869 | DBMET00510 | |
| 0.045 | 0.097 | 0.128 | Leukotriene C antagonist | 0.122 0.003 DBMET00510 0.128 0.003 DBMET00869 | DBMET00869 | |
| 0.016 | 0.068 | 0.05 | Glutamate (mGluR1) agonist | 0.05 0.005 DBMET00510 0.032 0.008 DBMET00869 | DBMET00510 | |
| 0.028 | 0.081 | 0.112 | AICAR transformylase inhibitor | 0.112 0.004 DBMET00510 0.086 0.006 DBMET00869 | DBMET00510 | |
| 0.119 | 0.173 | 0.175 | ATPase inhibitor | 0.167 0.075 DBMET00510 0.175 0.063 DBMET00869 | DBMET00869 | |
| 0.153 | 0.207 | 0.239 | Transcription factor STAT3 inhibitor | 0.215 0.116 DBMET00510 0.239 0.093 DBMET00869 | DBMET00869 | |
| 0.011 | 0.066 | 0.076 | Leukotriene B4 receptor 2 antagonist | 0.076 0.004 DBMET00510 0.061 0.004 DBMET00869 | DBMET00510 | |
| 0.023 | 0.079 | 0.077 | Adenosine deaminase inhibitor | 0.077 0.01 DBMET00510 0.064 0.017 DBMET00869 | DBMET00510 | |
| 0.008 | 0.063 | 0.088 | Prostaglandin EP2 agonist | 0.088 0.003 DBMET00510 0.08 0.004 DBMET00869 | DBMET00510 | |
| 0.038 | 0.093 | 0.087 | Matrix metalloproteinase inhibitor | 0.087 0.033 DBMET00510 0.078 0.038 DBMET00869 | DBMET00510 | |
| 0.022 | 0.078 | 0.132 | Dopamine D5 agonist | 0.085 0.005 DBMET00510 0.132 0.003 DBMET00869 | DBMET00869 | |
| 0.006 | 0.062 | 0.037 | Aminopeptidase A inhibitor | 0.037 0.005 DBMET00510 0.026 0.008 DBMET00869 | DBMET00510 | |
| 0.048 | 0.105 | 0.058 | Trypsin inhibitor | 0.058 0.053 DBMET00510 | DBMET00510 | |
| 0.07 | 0.128 | 0.124 | Anesthetic local | 0.124 0.064 DBMET00510 0.112 0.073 DBMET00869 | DBMET00510 | |
| 0.006 | 0.063 | 0.019 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.019 0.004 DBMET00510 0.016 0.006 DBMET00869 | DBMET00510 | |
| 0.029 | 0.088 | 0.075 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.074 0.004 DBMET00510 0.075 0.004 DBMET00869 | DBMET00869 | |
| 0.026 | 0.085 | 0.106 | Glutamate (mGluR8) agonist | 0.106 0.003 DBMET00510 0.082 0.004 DBMET00869 | DBMET00510 | |
| 0.003 | 0.063 | 0.021 | Integrin alphaVbeta5 antagonist | 0.021 0.004 DBMET00510 0.015 0.005 DBMET00869 | DBMET00510 | |
| 0.032 | 0.093 | 0.076 | Prolyl endopeptidase inhibitor | 0.076 0.012 DBMET00510 0.065 0.019 DBMET00869 | DBMET00510 | |
| 0.084 | 0.146 | 0.184 | Interleukin 8 antagonist | 0.177 0.02 DBMET00510 0.184 0.017 DBMET00869 | DBMET00869 | |
| 0.029 | 0.091 | 0.098 | Leukotriene C4 antagonist | 0.095 0.003 DBMET00510 0.098 0.003 DBMET00869 | DBMET00869 | |
| 0.078 | 0.143 | 0.27 | TRPA1 agonist | 0.21 0.009 DBMET00510 0.27 0.005 DBMET00869 | DBMET00869 | |
| 0.013 | 0.078 | 0.121 | Retinoid X receptor agonist | 0.121 0.004 DBMET00510 0.094 0.005 DBMET00869 | DBMET00510 | |
| 0.086 | 0.151 | 0.329 | Thrombolytic | 0.329 0.019 DBMET00510 0.287 0.026 DBMET00869 | DBMET00510 | |
| 0.013 | 0.078 | 0.172 | Prostaglandin agonist | 0.172 0.004 DBMET00510 0.161 0.004 DBMET00869 | DBMET00510 | |
| 0.071 | 0.137 | 0.1 | Acetylcholine muscarinic antagonist | 0.1 0.091 DBMET00510 0.096 0.095 DBMET00869 | DBMET00510 | |
| 0.03 | 0.095 | 0.104 | Beta 1 adrenoreceptor antagonist | 0.087 0.014 DBMET00510 0.104 0.009 DBMET00869 | DBMET00869 | |
| 0.002 | 0.068 | 0.012 | Integrin alpha5beta6 antagonist | 0.012 0.003 DBMET00510 0.009 0.004 DBMET00869 | DBMET00510 | |
| 0.007 | 0.072 | 0.057 | Integrin beta3 antagonist | 0.057 0.005 DBMET00510 0.017 0.016 DBMET00869 | DBMET00510 | |
| 0.012 | 0.079 | 0.024 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.024 0.008 DBMET00510 | DBMET00510 | |
| 0.026 | 0.092 | 0.04 | Aggrecanase 1 inhibitor | 0.04 0.026 DBMET00510 | DBMET00510 | |
| 0.004 | 0.071 | 0.033 | Integrin alpha4beta1 antagonist | 0.033 0.007 DBMET00510 0.023 0.009 DBMET00869 | DBMET00510 | |
| 0.01 | 0.078 | 0.062 | Integrin alphaVbeta3 antagonist | 0.062 0.005 DBMET00510 0.029 0.009 DBMET00869 | DBMET00510 | |
| 0.025 | 0.094 | 0.168 | Thromboxane antagonist | 0.168 0.004 DBMET00510 0.142 0.005 DBMET00869 | DBMET00510 | |
| 0.045 | 0.114 | 0.08 | Nicotinic alpha4beta2 receptor antagonist | 0.08 0.05 DBMET00510 | DBMET00510 | |
| 0.028 | 0.097 | 0.062 | Glucagon-like peptide 1 receptor antagonist | 0.062 0.008 DBMET00510 0.047 0.016 DBMET00869 | DBMET00510 | |
| 0.008 | 0.077 | 0.101 | Vitronectin receptor antagonist | 0.101 0.005 DBMET00510 0.03 0.01 DBMET00869 | DBMET00510 | |
| 0.022 | 0.091 | 0.157 | Thromboxane A2 antagonist | 0.157 0.004 DBMET00510 0.126 0.005 DBMET00869 | DBMET00510 | |
| 0.021 | 0.091 | 0.06 | Angiotensin AT1 receptor antagonist | 0.06 0.006 DBMET00510 0.046 0.023 DBMET00869 | DBMET00510 | |
| 0.042 | 0.111 | 0.086 | Amidase inhibitor | 0.075 0.042 DBMET00510 0.086 0.033 DBMET00869 | DBMET00869 | |
| 0.005 | 0.075 | 0.065 | Integrin alpha4beta7 antagonist | 0.065 0.005 DBMET00510 0.029 0.009 DBMET00869 | DBMET00510 | |
| 0.172 | 0.243 | 0.422 | Interleukin 2 agonist | 0.422 0.021 DBMET00510 0.408 0.025 DBMET00869 | DBMET00510 | |
| 0.015 | 0.086 | 0.352 | Integrin antagonist | 0.352 0.005 DBMET00510 0.15 0.01 DBMET00869 | DBMET00510 | |
| 0.004 | 0.076 | 0.012 | Integrin beta2 antagonist | 0.012 0.009 DBMET00510 | DBMET00510 | |
| 0.017 | 0.09 | 0.027 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.027 0.02 DBMET00510 0.026 0.022 DBMET00869 | DBMET00510 | |
| 0.021 | 0.093 | 0.069 | Integrin alpha5beta1 antagonist | 0.069 0.009 DBMET00510 0.049 0.019 DBMET00869 | DBMET00510 | |
| 0.075 | 0.148 | 0.2 | Folate antagonist | 0.2 0.01 DBMET00510 0.158 0.019 DBMET00869 | DBMET00510 | |
| 0.05 | 0.123 | 0.134 | Histamine N-methyltransferase inhibitor | 0.134 0.021 DBMET00510 0.121 0.029 DBMET00869 | DBMET00510 | |
| 0.005 | 0.078 | 0.445 | Free fatty acid receptor 1 agonist | 0.445 0.002 DBMET00510 0.231 0.003 DBMET00869 | DBMET00510 | |
| 0.024 | 0.098 | 0.04 | Nicotinic receptor alpha3 subunit antagonist | 0.04 0.035 DBMET00510 | DBMET00510 | |
| 0.009 | 0.084 | 0.066 | Integrin beta5 antagonist | 0.066 0.005 DBMET00510 0.026 0.01 DBMET00869 | DBMET00510 | |
| 0.005 | 0.08 | 0.034 | Ileal bile acid transport inhibitor | 0.033 0.005 DBMET00510 0.034 0.004 DBMET00869 | DBMET00869 | |
| 0.003 | 0.079 | 0.013 | Beta 3 adrenoreceptor agonist | 0.013 0.007 DBMET00869 | DBMET00869 | |
| 0.032 | 0.109 | 0.047 | Cytokine production stimulant | 0.047 0.036 DBMET00510 | DBMET00510 | |
| 0.073 | 0.149 | 0.262 | Bone formation stimulant | 0.259 0.023 DBMET00510 0.262 0.023 DBMET00869 | DBMET00869 | |
| 0.089 | 0.166 | 0.321 | Diuretic | 0.321 0.019 DBMET00510 0.258 0.029 DBMET00869 | DBMET00510 | |
| 0.035 | 0.112 | 0.123 | CD45 antagonist | 0.123 0.007 DBMET00510 0.118 0.008 DBMET00869 | DBMET00510 | |
| 0.05 | 0.128 | 0.068 | Calcium channel P-type blocker | 0.068 0.032 DBMET00510 0.062 0.049 DBMET00869 | DBMET00510 | |
| 0.055 | 0.133 | 0.14 | Estrogen receptor alpha antagonist | 0.089 0.036 DBMET00510 0.14 0.013 DBMET00869 | DBMET00869 | |
| 0.058 | 0.136 | 0.164 | Falcipain 3 inhibitor | 0.164 0.03 DBMET00510 0.143 0.04 DBMET00869 | DBMET00510 | |
| 0.045 | 0.123 | 0.131 | Glutamate (mGluR7) antagonist | 0.131 0.004 DBMET00510 0.118 0.005 DBMET00869 | DBMET00510 | |
| 0.007 | 0.085 | 0.017 | Angiotensin-converting enzyme 2 inhibitor | 0.017 0.013 DBMET00510 | DBMET00510 | |
| 0.024 | 0.102 | 0.038 | Neurokinin 2 agonist | 0.038 0.035 DBMET00510 | DBMET00510 | |
| 0.008 | 0.087 | 0.021 | Aminopeptidase P inhibitor | 0.021 0.019 DBMET00510 | DBMET00510 | |
| 0.003 | 0.082 | 0.009 | Phosphoribosylglycinamide formyltransferase inhibitor | 0.009 0.004 DBMET00510 | DBMET00510 | |
| 0.037 | 0.118 | 0.194 | Purinergic P2X1 antagonist | 0.194 0.004 DBMET00510 0.192 0.004 DBMET00869 | DBMET00510 | |
| 0.014 | 0.095 | 0.104 | Kainate receptor antagonist | 0.104 0.007 DBMET00510 0.063 0.015 DBMET00869 | DBMET00510 | |
| 0.018 | 0.099 | 0.053 | Angiotensin II receptor antagonist | 0.053 0.006 DBMET00510 0.036 0.021 DBMET00869 | DBMET00510 | |
| 0.003 | 0.085 | 0.042 | Glutamate (mGluR6) agonist | 0.042 0.002 DBMET00510 0.032 0.003 DBMET00869 | DBMET00510 | |
| 0.025 | 0.109 | 0.114 | Opioid delta receptor antagonist | 0.114 0.027 DBMET00869 | DBMET00869 | |
| 0.005 | 0.088 | 0.041 | Neutral endopeptidase inhibitor | 0.041 0.009 DBMET00510 | DBMET00510 | |
| 0.026 | 0.109 | 0.048 | Vanilloid 3 antagonist | 0.048 0.01 DBMET00510 0.041 0.02 DBMET00869 | DBMET00510 | |
| 0.09 | 0.174 | 0.3 | Amyloid beta aggregation inhibitor | 0.3 0.045 DBMET00869 | DBMET00869 | |
| 0.012 | 0.096 | 0.064 | Complement C3a chemotactic receptor antagonist | 0.064 0.02 DBMET00510 0.039 0.034 DBMET00869 | DBMET00510 | |
| 0.034 | 0.119 | 0.183 | Thromboxane synthase inhibitor | 0.183 0.004 DBMET00510 0.135 0.004 DBMET00869 | DBMET00510 | |
| 0.008 | 0.093 | 0.066 | Retinoid X beta receptor agonist | 0.066 0.004 DBMET00510 0.027 0.01 DBMET00869 | DBMET00510 | |
| 0.052 | 0.138 | 0.241 | 5-Lipoxygenase inhibitor | 0.169 0.032 DBMET00510 0.241 0.017 DBMET00869 | DBMET00869 | |
| 0.074 | 0.16 | 0.368 | Photosensitizer | 0.368 0.003 DBMET00510 0.343 0.004 DBMET00869 | DBMET00510 | |
| 0.008 | 0.094 | 0.076 | Squalene synthetase inhibitor | 0.076 0.009 DBMET00510 0.056 0.013 DBMET00869 | DBMET00510 | |
| 0.013 | 0.099 | 0.033 | LFA antagonist | 0.033 0.013 DBMET00510 | DBMET00510 | |
| 0.018 | 0.106 | 0.059 | Endothelin-converting enzyme inhibitor | 0.059 0.025 DBMET00510 | DBMET00510 | |
| 0.019 | 0.107 | 0.1 | GABA uptake inhibitor | 0.1 0.004 DBMET00510 0.068 0.008 DBMET00869 | DBMET00510 | |
| 0.024 | 0.112 | 0.042 | Neurotensin receptor antagonist | 0.042 0.035 DBMET00869 | DBMET00869 | |
| 0.028 | 0.117 | 0.126 | Glutamate (mGluR group III) antagonist | 0.126 0.004 DBMET00510 0.074 0.009 DBMET00869 | DBMET00510 | |
| 0.007 | 0.096 | 0.018 | Vitamin D receptor agonist | 0.018 0.009 DBMET00510 0.016 0.012 DBMET00869 | DBMET00510 | |
| 0.099 | 0.189 | 0.447 | Melanin inhibitor | 0.313 0.02 DBMET00510 0.447 0.009 DBMET00869 | DBMET00869 | |
| 0.017 | 0.106 | 0.04 | Estrogen-related receptor gamma antagonist | 0.032 0.012 DBMET00510 0.04 0.005 DBMET00869 | DBMET00869 | |
| 0.003 | 0.094 | 0.027 | N-Acetylated alpha-linked acidic dipeptidase inhibitor | 0.027 0.005 DBMET00510 0.014 0.011 DBMET00869 | DBMET00510 | |
| 0.012 | 0.103 | 0.032 | Plasmepsin I inhibitor | 0.032 0.019 DBMET00510 | DBMET00510 | |
| 0.029 | 0.121 | 0.195 | Leukotriene B4 antagonist | 0.166 0.004 DBMET00510 0.195 0.004 DBMET00869 | DBMET00869 | |
| 0.026 | 0.118 | 0.102 | Diacylglycerol O-acyltransferase inhibitor | 0.102 0.007 DBMET00510 0.059 0.026 DBMET00869 | DBMET00510 | |
| 0.034 | 0.126 | 0.685 | Phenylalanine 4-hydroxylase inhibitor | 0.599 0.002 DBMET00510 0.685 0.001 DBMET00869 | DBMET00869 | |
| 0.065 | 0.158 | 0.154 | AMP-activated protein kinase stimulant | 0.134 0.038 DBMET00510 0.154 0.026 DBMET00869 | DBMET00869 | |
| 0.02 | 0.113 | 0.066 | Integrin alpha2 antagonist | 0.066 0.006 DBMET00510 0.042 0.018 DBMET00869 | DBMET00510 | |
| 0.016 | 0.11 | 0.053 | Toll-Like receptor 2 agonist | 0.053 0.022 DBMET00510 0.037 0.033 DBMET00869 | DBMET00510 | |
| 0.004 | 0.098 | 0.014 | Adenosine A2a receptor agonist | 0.014 0.012 DBMET00510 | DBMET00510 | |
| 0.027 | 0.121 | 0.129 | Glutamate (mGluR4) antagonist | 0.129 0.004 DBMET00510 0.073 0.009 DBMET00869 | DBMET00510 | |
| 0.026 | 0.121 | 0.146 | NMDA receptor glycine site agonist | 0.146 0.005 DBMET00510 0.112 0.011 DBMET00869 | DBMET00510 | |
| 0.018 | 0.115 | 0.055 | Opioid mu receptor agonist | 0.055 0.026 DBMET00869 | DBMET00869 | |
| 0.005 | 0.102 | 0.169 | Integrin alpha4 antagonist | 0.169 0.004 DBMET00510 0.087 0.007 DBMET00869 | DBMET00510 | |
| 0.027 | 0.126 | 0.102 | Opioid mu receptor antagonist | 0.102 0.031 DBMET00869 | DBMET00869 | |
| 0.017 | 0.116 | 0.028 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.028 0.015 DBMET00510 | DBMET00510 | |
| 0.02 | 0.12 | 0.052 | Leukocyte elastase inhibitor | 0.052 0.022 DBMET00510 0.042 0.031 DBMET00869 | DBMET00510 | |
| 0.019 | 0.119 | 0.058 | Retinoid X alpha receptor antagonist | 0.058 0.004 DBMET00510 0.044 0.01 DBMET00869 | DBMET00510 | |
| 0.009 | 0.109 | 0.197 | GP IIb/IIIa receptor antagonist | 0.197 0.007 DBMET00510 0.083 0.021 DBMET00869 | DBMET00510 | |
| 0.004 | 0.104 | 0.052 | Kainate receptor 1 antagonist | 0.052 0.005 DBMET00510 0.026 0.012 DBMET00869 | DBMET00510 | |
| 0.009 | 0.11 | 0.084 | Lysine carboxypeptidase inhibitor | 0.084 0.004 DBMET00510 0.054 0.007 DBMET00869 | DBMET00510 | |
| 0.024 | 0.125 | 0.123 | Maillard reaction inhibitor | 0.116 0.011 DBMET00510 0.123 0.01 DBMET00869 | DBMET00869 | |
| 0.006 | 0.108 | 0.124 | Thyroid hormone alpha antagonist | 0.124 0.003 DBMET00510 0.121 0.003 DBMET00869 | DBMET00510 | |
| 0.068 | 0.17 | 0.618 | Alpha-N-acetylglucosaminidase inhibitor | 0.618 0.004 DBMET00510 0.406 0.009 DBMET00869 | DBMET00510 | |
| 0.04 | 0.143 | 0.107 | Caspase 9 inhibitor | 0.107 0.012 DBMET00510 0.081 0.022 DBMET00869 | DBMET00510 | |
| 0.005 | 0.108 | 0.042 | Integrin beta7 antagonist | 0.042 0.007 DBMET00510 0.018 0.015 DBMET00869 | DBMET00510 | |
| 0.051 | 0.155 | 0.105 | MDM2 inhibitor | 0.105 0.005 DBMET00510 0.087 0.013 DBMET00869 | DBMET00510 | |
| 0.021 | 0.125 | 0.07 | Retinoid X receptor antagonist | 0.07 0.004 DBMET00510 0.056 0.008 DBMET00869 | DBMET00510 | |
| 0.011 | 0.117 | 0.028 | Sodium/glucose cotransporter inhibitor | 0.026 0.016 DBMET00510 0.028 0.014 DBMET00869 | DBMET00869 | |
| 0.055 | 0.161 | 0.689 | GABA C receptor agonist | 0.689 0.002 DBMET00510 0.545 0.003 DBMET00869 | DBMET00510 | |
| 0.008 | 0.114 | 0.185 | Leukotriene B4 receptor 1 antagonist | 0.185 0.003 DBMET00510 0.099 0.004 DBMET00869 | DBMET00510 | |
| 0.044 | 0.151 | 0.084 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.084 0.03 DBMET00510 | DBMET00510 | |
| 0.004 | 0.111 | 0.118 | VLA-4 antagonist | 0.118 0.005 DBMET00510 0.074 0.009 DBMET00869 | DBMET00510 | |
| 0.055 | 0.162 | 0.641 | Ferrochelatase inhibitor | 0.641 0.001 DBMET00510 0.459 0.003 DBMET00869 | DBMET00510 | |
| 0.015 | 0.123 | 0.052 | Glutamate (mGluR group II) antagonist | 0.052 0.014 DBMET00510 | DBMET00510 | |
| 0.011 | 0.118 | 0.039 | Retinoid X beta receptor antagonist | 0.039 0.003 DBMET00510 0.025 0.007 DBMET00869 | DBMET00510 | |
| 0.059 | 0.167 | 0.19 | Interleukin 1 beta converting enzyme inhibitor | 0.19 0.007 DBMET00510 0.183 0.008 DBMET00869 | DBMET00510 | |
| 0.006 | 0.114 | 0.079 | Arginase inhibitor | 0.079 0.006 DBMET00510 0.063 0.009 DBMET00869 | DBMET00510 | |
| 0.046 | 0.154 | 0.119 | Opioid antagonist | 0.119 0.037 DBMET00869 | DBMET00869 | |
| 0.022 | 0.131 | 0.09 | Glutamate (mGluR group III) agonist | 0.09 0.011 DBMET00510 0.056 0.02 DBMET00869 | DBMET00510 | |
| 0.002 | 0.112 | 0.077 | Thyroid hormone beta agonist | 0.033 0.003 DBMET00510 0.077 0.002 DBMET00869 | DBMET00869 | |
| 0.008 | 0.118 | 0.044 | Integrin alphaVbeta1 antagonist | 0.044 0.005 DBMET00510 0.027 0.007 DBMET00869 | DBMET00510 | |
| 0.012 | 0.122 | 0.032 | Opioid delta receptor agonist | 0.032 0.03 DBMET00869 | DBMET00869 | |
| 0.012 | 0.123 | 0.027 | ICAM 1 antagonist | 0.027 0.009 DBMET00510 0.024 0.014 DBMET00869 | DBMET00510 | |
| 0.069 | 0.18 | 0.363 | Aldehyde dehydrogenase inhibitor | 0.312 0.011 DBMET00510 0.363 0.007 DBMET00869 | DBMET00869 | |
| 0.012 | 0.123 | 0.135 | Thyroid hormone agonist | 0.08 0.003 DBMET00510 0.135 0.002 DBMET00869 | DBMET00869 | |
| 0.038 | 0.15 | 0.096 | Analgesic, opioid | 0.096 0.033 DBMET00869 | DBMET00869 | |
| 0.069 | 0.184 | 0.121 | Electron transport complex I inhibitor | 0.11 0.063 DBMET00510 0.121 0.045 DBMET00869 | DBMET00869 | |
| 0.01 | 0.125 | 0.051 | Nicotinic acid receptor 2 antagonist | 0.051 0.004 DBMET00510 0.037 0.007 DBMET00869 | DBMET00510 | |
| 0.034 | 0.149 | 0.149 | Prostaglandin F2 alpha antagonist | 0.149 0.005 DBMET00510 0.123 0.006 DBMET00869 | DBMET00510 | |
| 0.072 | 0.189 | 0.279 | Interleukin 4 antagonist | 0.216 0.018 DBMET00510 0.279 0.01 DBMET00869 | DBMET00869 | |
| 0.036 | 0.153 | 0.079 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.057 0.05 DBMET00510 0.079 0.02 DBMET00869 | DBMET00869 | |
| 0.067 | 0.183 | 0.329 | DOPA decarboxylase inhibitor | 0.261 0.003 DBMET00510 0.329 0.002 DBMET00869 | DBMET00869 | |
| 0.004 | 0.121 | 0.025 | Egl nine homolog 1 inhibitor | 0.023 0.005 DBMET00510 0.025 0.005 DBMET00869 | DBMET00869 | |
| 0.03 | 0.148 | 0.064 | Botulinum neurotoxin type A inhibitor | 0.064 0.032 DBMET00510 0.061 0.036 DBMET00869 | DBMET00510 | |
| 0.002 | 0.12 | 0.044 | Thromboxane agonist | 0.044 0.002 DBMET00510 0.031 0.003 DBMET00869 | DBMET00510 | |
| 0.017 | 0.135 | 0.046 | Matrix metalloproteinase 1 inhibitor | 0.046 0.041 DBMET00510 | DBMET00510 | |
| 0.004 | 0.124 | 0.061 | AMPA 1 receptor antagonist | 0.061 0.009 DBMET00510 0.036 0.017 DBMET00869 | DBMET00510 | |
| 0.003 | 0.123 | 0.012 | Egl nine homolog 3 inhibitor | 0.012 0.008 DBMET00510 | DBMET00510 | |
| 0.06 | 0.181 | 0.119 | Hematopoietic | 0.119 0.022 DBMET00510 0.098 0.038 DBMET00869 | DBMET00510 | |
| 0.035 | 0.156 | 0.102 | Phospholipase D inhibitor | 0.102 0.013 DBMET00510 0.076 0.04 DBMET00869 | DBMET00510 | |
| 0.018 | 0.139 | 0.093 | Mannosidase inhibitor | 0.093 0.006 DBMET00510 0.071 0.011 DBMET00869 | DBMET00510 | |
| 0.01 | 0.132 | 0.023 | Methylmalonyl-CoA mutase inhibitor | 0.023 0.005 DBMET00510 0.019 0.011 DBMET00869 | DBMET00510 | |
| 0.032 | 0.155 | 0.067 | Dihydroorotate oxidase inhibitor | 0.067 0.02 DBMET00510 0.062 0.026 DBMET00869 | DBMET00510 | |
| 0.047 | 0.17 | 0.178 | Bronchodilator | 0.147 0.032 DBMET00510 0.178 0.023 DBMET00869 | DBMET00869 | |
| 0.008 | 0.131 | 0.063 | AMPA 3 receptor antagonist | 0.063 0.005 DBMET00510 0.042 0.012 DBMET00869 | DBMET00510 | |
| 0.059 | 0.182 | 0.099 | Acetylcholine antagonist | 0.099 0.093 DBMET00510 | DBMET00510 | |
| 0.024 | 0.148 | 0.086 | Alpha-mannosidase inhibitor | 0.086 0.009 DBMET00510 0.071 0.016 DBMET00869 | DBMET00510 | |
| 0.022 | 0.146 | 0.033 | Adenosine uptake inhibitor | 0.033 0.029 DBMET00510 | DBMET00510 | |
| 0.019 | 0.145 | 0.093 | AMPA 4 receptor antagonist | 0.093 0.005 DBMET00510 0.056 0.012 DBMET00869 | DBMET00510 | |
| 0.008 | 0.134 | 0.028 | Sodium/glucose cotransporter 2 inhibitor | 0.027 0.017 DBMET00510 0.028 0.015 DBMET00869 | DBMET00869 | |
| 0.059 | 0.185 | 0.103 | Cholinergic antagonist | 0.103 0.091 DBMET00510 | DBMET00510 | |
| 0.01 | 0.136 | 0.027 | Glutamate (mGluR2) antagonist | 0.027 0.026 DBMET00510 | DBMET00510 | |
| 0.019 | 0.146 | 0.062 | Dihydrofolate reductase inhibitor | 0.062 0.009 DBMET00510 0.055 0.014 DBMET00869 | DBMET00510 | |
| 0.131 | 0.258 | 0.244 | Peptidyltransferase inhibitor | 0.235 0.062 DBMET00510 0.244 0.055 DBMET00869 | DBMET00869 | |
| 0.044 | 0.173 | 0.089 | Opioid kappa receptor antagonist | 0.089 0.047 DBMET00869 | DBMET00869 | |
| 0.015 | 0.144 | 0.126 | Ornithine carbamoyltransferase inhibitor | 0.126 0.012 DBMET00510 0.071 0.025 DBMET00869 | DBMET00510 | |
| 0.015 | 0.145 | 0.026 | Complement factor 1s inhibitor | 0.026 0.017 DBMET00510 | DBMET00510 | |
| 0.052 | 0.183 | 0.171 | Anabolic | 0.166 0.011 DBMET00510 0.171 0.009 DBMET00869 | DBMET00869 | |
| 0.043 | 0.174 | 0.181 | Glutamate (mGluR6) antagonist | 0.181 0.003 DBMET00510 0.121 0.005 DBMET00869 | DBMET00510 | |
| 0.033 | 0.164 | 0.066 | Sirtuin 1 inhibitor | 0.065 0.051 DBMET00510 0.066 0.05 DBMET00869 | DBMET00869 | |
| 0.073 | 0.204 | 0.137 | Acetylcholine M1 receptor antagonist | 0.137 0.088 DBMET00510 0.126 0.1 DBMET00869 | DBMET00510 | |
| 0.016 | 0.148 | 0.048 | Opioid agonist | 0.048 0.042 DBMET00869 | DBMET00869 | |
| 0.017 | 0.15 | 0.043 | Cholecystokinin B agonist | 0.043 0.021 DBMET00510 0.035 0.03 DBMET00869 | DBMET00510 | |
| 0.064 | 0.197 | 0.308 | Adenylate kinase inhibitor | 0.308 0.006 DBMET00510 0.213 0.013 DBMET00869 | DBMET00510 | |
| 0.019 | 0.152 | 0.163 | Acyl-CoA dehydrogenase inhibitor | 0.163 0.008 DBMET00510 0.087 0.02 DBMET00869 | DBMET00510 | |
| 0.027 | 0.162 | 0.152 | Leukotriene synthesis inhibitor | 0.152 0.009 DBMET00510 0.152 0.009 DBMET00869 | DBMET00869 | |
| 0.025 | 0.161 | 0.087 | Dopamine beta hydroxylase inhibitor | 0.078 0.005 DBMET00510 0.087 0.004 DBMET00869 | DBMET00869 | |
| 0.014 | 0.15 | 0.101 | Macrophage elastase inhibitor | 0.101 0.009 DBMET00510 0.059 0.019 DBMET00869 | DBMET00510 | |
| 0.029 | 0.165 | 0.052 | Carbonic anhydrase II stimulant | 0.052 0.036 DBMET00510 | DBMET00510 | |
| 0.031 | 0.167 | 0.074 | Angiotensin-converting enzyme inhibitor | 0.074 0.017 DBMET00510 0.062 0.027 DBMET00869 | DBMET00510 | |
| 0.02 | 0.157 | 0.256 | Argininosuccinate synthase inhibitor | 0.256 0.005 DBMET00510 0.174 0.009 DBMET00869 | DBMET00510 | |
| 0.009 | 0.146 | 0.052 | Phosphoglycerate kinase inhibitor | 0.052 0.013 DBMET00510 0.046 0.016 DBMET00869 | DBMET00510 | |
| 0.046 | 0.183 | 0.282 | Creatine kinase inhibitor | 0.221 0.008 DBMET00510 0.282 0.004 DBMET00869 | DBMET00869 | |
| 0.008 | 0.145 | 0.08 | G protein-coupled receptor agonist | 0.08 0.008 DBMET00510 0.04 0.025 DBMET00869 | DBMET00510 | |
| 0.027 | 0.165 | 0.054 | Squalene epoxidase inhibitor | 0.047 0.041 DBMET00510 0.054 0.027 DBMET00869 | DBMET00869 | |
| 0.012 | 0.151 | 0.075 | Dihydropteroate synthase inhibitor | 0.075 0.007 DBMET00510 0.074 0.008 DBMET00869 | DBMET00510 | |
| 0.115 | 0.255 | 0.467 | Lipoxygenase inhibitor | 0.334 0.056 DBMET00510 0.467 0.024 DBMET00869 | DBMET00869 | |
| 0.016 | 0.157 | 0.078 | Membrane dipeptidase inhibitor | 0.078 0.005 DBMET00510 0.047 0.018 DBMET00869 | DBMET00510 | |
| 0.009 | 0.149 | 0.046 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.029 0.026 DBMET00510 0.046 0.013 DBMET00869 | DBMET00869 | |
| 0.012 | 0.154 | 0.172 | ATP citrate lysase inhibitor | 0.113 0.003 DBMET00510 0.172 0.003 DBMET00869 | DBMET00869 | |
| 0.007 | 0.149 | 0.059 | Retinoid X gamma receptor agonist | 0.059 0.005 DBMET00510 0.026 0.013 DBMET00869 | DBMET00510 | |
| 0.03 | 0.172 | 0.544 | Glutamate decarboxylase inhibitor | 0.373 0.003 DBMET00510 0.544 0.002 DBMET00869 | DBMET00869 | |
| 0.008 | 0.151 | 0.098 | 5-Alpha-reductase inhibitor | 0.098 0.01 DBMET00510 0.08 0.012 DBMET00869 | DBMET00510 | |
| 0.027 | 0.17 | 0.097 | Glutamate receptor agonist | 0.097 0.039 DBMET00510 | DBMET00510 | |
| 0.023 | 0.167 | 0.364 | Aconitate hydratase inhibitor | 0.364 0.002 DBMET00510 0.189 0.003 DBMET00869 | DBMET00510 | |
| 0.012 | 0.156 | 0.094 | Antimetabolite | 0.094 0.017 DBMET00510 0.06 0.025 DBMET00869 | DBMET00510 | |
| 0.006 | 0.152 | 0.038 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.038 0.005 DBMET00510 0.031 0.007 DBMET00869 | DBMET00510 | |
| 0.056 | 0.203 | 0.193 | Caspase 3 inhibitor | 0.193 0.011 DBMET00510 0.181 0.014 DBMET00869 | DBMET00510 | |
| 0.005 | 0.152 | 0.046 | NMDA receptor glycine site antagonist | 0.046 0.007 DBMET00510 0.032 0.012 DBMET00869 | DBMET00510 | |
| 0.118 | 0.265 | 0.444 | 12-Lipoxygenase inhibitor | 0.322 0.068 DBMET00510 0.444 0.029 DBMET00869 | DBMET00869 | |
| 0.112 | 0.259 | 0.168 | Histone acetyltransferase inhibitor | 0.153 0.135 DBMET00510 0.168 0.116 DBMET00869 | DBMET00869 | |
| 0.011 | 0.159 | 0.124 | Ribonucleoside-diphosphate reductase inhibitor | 0.116 0.016 DBMET00510 0.124 0.015 DBMET00869 | DBMET00869 | |
| 0.05 | 0.198 | 0.202 | Bile acid receptor antagonist | 0.164 0.005 DBMET00510 0.202 0.004 DBMET00869 | DBMET00869 | |
| 0.052 | 0.2 | 0.209 | GABA C receptor rho-1 antagonist | 0.209 0.007 DBMET00510 0.161 0.017 DBMET00869 | DBMET00510 | |
| 0.007 | 0.155 | 0.02 | Integrin beta6 antagonist | 0.02 0.004 DBMET00510 0.02 0.004 DBMET00869 | DBMET00869 | |
| 0.023 | 0.173 | 0.076 | Collagenase 3 inhibitor | 0.076 0.027 DBMET00510 0.059 0.042 DBMET00869 | DBMET00510 | |
| 0.011 | 0.16 | 0.12 | Ribonucleotide reductase inhibitor | 0.113 0.018 DBMET00510 0.12 0.017 DBMET00869 | DBMET00869 | |
| 0.053 | 0.203 | 0.106 | Protein kinase C gamma inhibitor | 0.093 0.09 DBMET00510 0.106 0.068 DBMET00869 | DBMET00869 | |
| 0.13 | 0.281 | 0.237 | Transcription factor STAT inhibitor | 0.212 0.122 DBMET00510 0.237 0.096 DBMET00869 | DBMET00869 | |
| 0.07 | 0.221 | 0.366 | Protein kinase stimulant | 0.303 0.016 DBMET00510 0.366 0.01 DBMET00869 | DBMET00869 | |
| 0.044 | 0.196 | 0.265 | Prolactin inhibitor | 0.229 0.005 DBMET00510 0.265 0.004 DBMET00869 | DBMET00869 | |
| 0.024 | 0.177 | 0.069 | Androgen agonist | 0.069 0.032 DBMET00510 0.069 0.031 DBMET00869 | DBMET00869 | |
| 0.004 | 0.158 | 0.037 | Nicotinic acid receptor 1 antagonist | 0.033 0.004 DBMET00510 0.037 0.004 DBMET00869 | DBMET00869 | |
| 0.026 | 0.18 | 0.765 | Porphobilinogen synthase inhibitor | 0.765 0.002 DBMET00510 0.732 0.002 DBMET00869 | DBMET00510 | |
| 0.015 | 0.169 | 0.077 | Thymidylate synthase inhibitor | 0.077 0.009 DBMET00510 0.06 0.017 DBMET00869 | DBMET00510 | |
| 0.04 | 0.194 | 0.184 | Glycine receptor agonist | 0.184 0.005 DBMET00510 0.155 0.006 DBMET00869 | DBMET00510 | |
| 0.085 | 0.24 | 0.2 | P-glycoprotein inhibitor | 0.178 0.081 DBMET00510 0.2 0.064 DBMET00869 | DBMET00869 | |
| 0.005 | 0.16 | 0.044 | Cholecystokinin A antagonist | 0.044 0.022 DBMET00510 | DBMET00510 | |
| 0.011 | 0.169 | 0.037 | Integrin alpha2beta1 antagonist | 0.037 0.007 DBMET00510 | DBMET00510 | |
| 0.004 | 0.162 | 0.042 | Thromboxane A2 agonist | 0.042 0.002 DBMET00510 0.029 0.003 DBMET00869 | DBMET00510 | |
| 0.076 | 0.235 | 0.168 | Sigma receptor agonist | 0.13 0.103 DBMET00510 0.168 0.074 DBMET00869 | DBMET00869 | |
| 0.005 | 0.163 | 0.033 | Cholecystokinin B antagonist | 0.033 0.019 DBMET00510 | DBMET00510 | |
| 0.022 | 0.182 | 0.246 | Leukotriene antagonist | 0.21 0.005 DBMET00510 0.246 0.004 DBMET00869 | DBMET00869 | |
| 0.004 | 0.165 | 0.087 | Estrogen receptor alpha agonist | 0.087 0.01 DBMET00869 | DBMET00869 | |
| 0.129 | 0.291 | 0.261 | Nitric-oxide synthase stimulant | 0.245 0.036 DBMET00510 0.261 0.026 DBMET00869 | DBMET00869 | |
| 0.025 | 0.188 | 0.075 | Heparanase inhibitor | 0.075 0.009 DBMET00510 0.068 0.014 DBMET00869 | DBMET00510 | |
| 0.022 | 0.185 | 0.092 | Kainate receptor agonist | 0.092 0.003 DBMET00510 0.068 0.005 DBMET00869 | DBMET00510 | |
| 0.007 | 0.17 | 0.032 | 5-Alpha-reductase 2 inhibitor | 0.032 0.009 DBMET00510 0.021 0.012 DBMET00869 | DBMET00510 | |
| 0.047 | 0.211 | 0.113 | GABA receptor agonist | 0.113 0.063 DBMET00510 | DBMET00510 | |
| 0.009 | 0.174 | 0.279 | Fumarate hydratase inhibitor | 0.279 0.003 DBMET00510 0.111 0.005 DBMET00869 | DBMET00510 | |
| 0.028 | 0.196 | 0.087 | Heme oxygenase inhibitor | 0.087 0.004 DBMET00510 0.067 0.005 DBMET00869 | DBMET00510 | |
| 0.058 | 0.227 | 0.096 | T cell inhibitor | 0.096 0.029 DBMET00510 0.081 0.062 DBMET00869 | DBMET00510 | |
| 0.019 | 0.188 | 0.051 | Thymidine kinase inhibitor | 0.051 0.018 DBMET00510 | DBMET00510 | |
| 0.006 | 0.177 | 0.154 | Leukotriene D4 antagonist | 0.154 0.005 DBMET00510 0.109 0.005 DBMET00869 | DBMET00510 | |
| 0.015 | 0.186 | 0.031 | Hedgehog signaling activator | 0.031 0.011 DBMET00510 0.028 0.017 DBMET00869 | DBMET00510 | |
| 0.139 | 0.311 | 0.497 | GABA C receptor rho-3 antagonist | 0.487 0.03 DBMET00510 0.497 0.027 DBMET00869 | DBMET00869 | |
| 0.043 | 0.215 | 0.352 | Cholesterol synthesis inhibitor | 0.327 0.009 DBMET00510 0.352 0.007 DBMET00869 | DBMET00869 | |
| 0.029 | 0.201 | 0.087 | Androgen antagonist | 0.087 0.057 DBMET00869 | DBMET00869 | |
| 0.034 | 0.208 | 0.139 | Glycine receptor antagonist | 0.139 0.01 DBMET00510 0.103 0.03 DBMET00869 | DBMET00510 | |
| 0.033 | 0.208 | 0.356 | Macrophage migration inhibitory factor inhibitor | 0.194 0.008 DBMET00510 0.356 0.004 DBMET00869 | DBMET00869 | |
| 0.006 | 0.181 | 0.06 | Cholecystokinin antagonist | 0.06 0.019 DBMET00510 | DBMET00510 | |
| 0.046 | 0.221 | 0.465 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.465 0.003 DBMET00510 0.354 0.004 DBMET00869 | DBMET00510 | |
| 0.007 | 0.183 | 0.021 | Antibiotic Anthracycline-like | 0.02 0.011 DBMET00510 0.021 0.009 DBMET00869 | DBMET00869 | |
| 0.068 | 0.244 | 0.178 | Cell wall synthesis inhibitor | 0.178 0.041 DBMET00510 0.166 0.051 DBMET00869 | DBMET00510 | |
| 0.018 | 0.196 | 0.294 | Phosphofructokinase-1 inhibitor | 0.294 0.005 DBMET00510 0.241 0.008 DBMET00869 | DBMET00510 | |
| 0.045 | 0.223 | 0.25 | GABA B receptor agonist | 0.192 0.004 DBMET00510 0.25 0.003 DBMET00869 | DBMET00869 | |
| 0.023 | 0.202 | 0.084 | Histamine H1 receptor antagonist | 0.084 0.053 DBMET00510 | DBMET00510 | |
| 0.034 | 0.214 | 0.329 | Glutamate dehydrogenase inhibitor | 0.329 0.005 DBMET00510 0.216 0.009 DBMET00869 | DBMET00510 | |
| 0.006 | 0.187 | 0.06 | Diacylglycerol O-acyltransferase 1 inhibitor | 0.06 0.007 DBMET00510 | DBMET00510 | |
| 0.134 | 0.315 | 0.494 | Apoptosis antagonist | 0.494 0.021 DBMET00510 0.493 0.021 DBMET00869 | DBMET00510 | |
| 0.049 | 0.234 | 0.122 | Granulocyte macrophage colony stimulating factor agonist | 0.122 0.015 DBMET00510 0.111 0.023 DBMET00869 | DBMET00510 | |
| 0.008 | 0.195 | 0.021 | Retinoic acid beta receptor agonist | 0.021 0.012 DBMET00510 | DBMET00510 | |
| 0.009 | 0.197 | 0.065 | AMPA receptor antagonist | 0.065 0.023 DBMET00510 | DBMET00510 | |
| 0.004 | 0.195 | 0.128 | Prostaglandin D2 antagonist | 0.128 0.004 DBMET00510 0.04 0.008 DBMET00869 | DBMET00510 | |
| 0.02 | 0.211 | 0.06 | VCAM-1 antagonist | 0.06 0.005 DBMET00510 0.05 0.009 DBMET00869 | DBMET00510 | |
| 0.02 | 0.212 | 0.06 | VCAM antagonist | 0.06 0.005 DBMET00510 0.05 0.009 DBMET00869 | DBMET00510 | |
| 0.015 | 0.21 | 0.064 | Glutamate (mGluR3) agonist | 0.057 0.004 DBMET00510 0.064 0.003 DBMET00869 | DBMET00869 | |
| 0.018 | 0.213 | 0.095 | Selectin antagonist | 0.095 0.029 DBMET00510 0.094 0.03 DBMET00869 | DBMET00510 | |
| 0.024 | 0.22 | 0.081 | Acetylcholine nicotinic antagonist | 0.081 0.054 DBMET00510 0.072 0.066 DBMET00869 | DBMET00510 | |
| 0.03 | 0.226 | 0.236 | Protein-tyrosine phosphatase 1B inhibitor | 0.229 0.021 DBMET00510 0.236 0.02 DBMET00869 | DBMET00869 | |
| 0.081 | 0.278 | 0.305 | Interferon gamma antagonist | 0.271 0.025 DBMET00510 0.305 0.019 DBMET00869 | DBMET00869 | |
| 0.047 | 0.246 | 0.201 | Electrolyte absorption antagonist | 0.201 0.008 DBMET00510 0.133 0.028 DBMET00869 | DBMET00510 | |
| 0.03 | 0.229 | 0.317 | GABA aminotransferase inhibitor | 0.262 0.004 DBMET00510 0.317 0.003 DBMET00869 | DBMET00869 | |
| 0.075 | 0.274 | 0.545 | Insulin secretagoues | 0.545 0.005 DBMET00510 0.466 0.005 DBMET00869 | DBMET00510 | |
| 0.095 | 0.294 | 0.281 | DNA damaging | 0.28 0.066 DBMET00510 0.281 0.065 DBMET00869 | DBMET00869 | |
| 0.017 | 0.218 | 0.246 | Carbamoyl phosphate synthetase inhibitor | 0.246 0.005 DBMET00510 0.162 0.01 DBMET00869 | DBMET00510 | |
| 0.006 | 0.21 | 0.104 | Prostacyclin antagonist | 0.104 0.004 DBMET00510 0.076 0.006 DBMET00869 | DBMET00510 | |
| 0.172 | 0.377 | 0.44 | Antiinflammatory | 0.407 0.135 DBMET00510 0.44 0.116 DBMET00869 | DBMET00869 | |
| 0.025 | 0.231 | 0.483 | Monophenol monooxygenase inhibitor | 0.277 0.021 DBMET00510 0.483 0.008 DBMET00869 | DBMET00869 | |
| 0.015 | 0.223 | 0.159 | Plasminogen activator inhibitor antagonist | 0.159 0.005 DBMET00510 0.143 0.005 DBMET00869 | DBMET00510 | |
| 0.094 | 0.305 | 0.381 | Thyroid hormone antagonist | 0.335 0.079 DBMET00510 0.381 0.062 DBMET00869 | DBMET00869 | |
| 0.021 | 0.232 | 0.106 | Na+ K+ transporting ATPase inhibitor | 0.106 0.027 DBMET00510 0.103 0.029 DBMET00869 | DBMET00510 | |
| 0.009 | 0.22 | 0.063 | Purinergic P2Y antagonist | 0.063 0.018 DBMET00510 0.041 0.036 DBMET00869 | DBMET00510 | |
| 0.008 | 0.221 | 0.036 | Retinoid X gamma receptor antagonist | 0.036 0.006 DBMET00510 0.028 0.016 DBMET00869 | DBMET00510 | |
| 0.011 | 0.225 | 0.033 | Caspase 6 inhibitor | 0.033 0.015 DBMET00510 0.029 0.025 DBMET00869 | DBMET00510 | |
| 0.083 | 0.298 | 0.145 | Focal adhesion kinase 2 inhibitor | 0.145 0.14 DBMET00510 | DBMET00510 | |
| 0.052 | 0.268 | 0.227 | Estrogen antagonist | 0.109 0.077 DBMET00510 0.227 0.01 DBMET00869 | DBMET00869 | |
| 0.005 | 0.223 | 0.016 | Kainate receptor 3 antagonist | 0.016 0.014 DBMET00510 | DBMET00510 | |
| 0.041 | 0.259 | 0.429 | Triose-phosphate isomerase inhibitor | 0.429 0.003 DBMET00510 0.312 0.005 DBMET00869 | DBMET00510 | |
| 0.061 | 0.28 | 0.245 | Arachidonic acid antagonist | 0.245 0.006 DBMET00510 0.244 0.007 DBMET00869 | DBMET00510 | |
| 0.006 | 0.226 | 0.115 | Urate transporter 1 inhibitor | 0.115 0.005 DBMET00510 0.107 0.005 DBMET00869 | DBMET00510 | |
| 0.052 | 0.275 | 0.245 | Cyclooxygenase 3 inhibitor | 0.221 0.013 DBMET00510 0.245 0.009 DBMET00869 | DBMET00869 | |
| 0.004 | 0.227 | 0.018 | Telomerase stimulant | 0.018 0.01 DBMET00510 | DBMET00510 | |
| 0.071 | 0.294 | 0.133 | DNA repair enzyme inhibitor | 0.133 0.05 DBMET00510 0.126 0.061 DBMET00869 | DBMET00510 | |
| 0.068 | 0.292 | 0.38 | Immunostimulant | 0.368 0.059 DBMET00510 0.38 0.056 DBMET00869 | DBMET00869 | |
| 0.002 | 0.227 | 0.035 | Carbonic anhydrase VIII inhibitor | 0.035 0.004 DBMET00510 0.016 0.012 DBMET00869 | DBMET00510 | |
| 0.002 | 0.227 | 0.035 | Carbonic anhydrase X inhibitor | 0.035 0.004 DBMET00510 0.016 0.012 DBMET00869 | DBMET00510 | |
| 0.009 | 0.234 | 0.081 | Fructose-1,6-bisphosphatase inhibitor | 0.081 0.007 DBMET00510 0.07 0.012 DBMET00869 | DBMET00510 | |
| 0.124 | 0.35 | 0.668 | Histamine release inhibitor | 0.647 0.007 DBMET00510 0.668 0.005 DBMET00869 | DBMET00869 | |
| 0.022 | 0.25 | 0.056 | Integrin alpha1beta1 antagonist | 0.056 0.005 DBMET00510 0.042 0.017 DBMET00869 | DBMET00510 | |
| 0.079 | 0.308 | 0.457 | Succinate dehydrogenase inhibitor | 0.457 0.003 DBMET00510 0.422 0.004 DBMET00869 | DBMET00510 | |
| 0.073 | 0.303 | 0.339 | Non-steroidal antiinflammatory agent | 0.339 0.021 DBMET00510 0.338 0.021 DBMET00869 | DBMET00510 | |
| 0.018 | 0.25 | 0.095 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.063 0.026 DBMET00510 0.095 0.011 DBMET00869 | DBMET00869 | |
| 0.009 | 0.242 | 0.136 | Carbonic anhydrase VB inhibitor | 0.111 0.014 DBMET00510 0.136 0.01 DBMET00869 | DBMET00869 | |
| 0.005 | 0.241 | 0.048 | HMG CoA reductase inhibitor | 0.048 0.008 DBMET00510 0.039 0.015 DBMET00869 | DBMET00510 | |
| 0.041 | 0.277 | 0.372 | Amylase inhibitor | 0.277 0.022 DBMET00510 0.372 0.011 DBMET00869 | DBMET00869 | |
| 0.068 | 0.304 | 0.219 | GABA C receptor rho-2 antagonist | 0.219 0.02 DBMET00510 0.2 0.029 DBMET00869 | DBMET00510 | |
| 0.015 | 0.253 | 0.395 | Biliverdin reductase inhibitor | 0.395 0.002 DBMET00510 0.263 0.004 DBMET00869 | DBMET00510 | |
| 0.005 | 0.243 | 0.034 | Thyroid hormone alpha agonist | 0.034 0.004 DBMET00510 0.034 0.004 DBMET00869 | DBMET00869 | |
| 0.005 | 0.244 | 0.018 | Purinergic P2Y1 agonist | 0.018 0.008 DBMET00510 0.016 0.01 DBMET00869 | DBMET00510 | |
| 0.083 | 0.322 | 0.456 | Phospholipase C inhibitor | 0.382 0.012 DBMET00510 0.456 0.008 DBMET00869 | DBMET00869 | |
| 0.003 | 0.243 | 0.029 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.029 0.018 DBMET00510 | DBMET00510 | |
| 0.037 | 0.277 | 0.362 | Cell adhesion molecule inhibitor | 0.362 0.005 DBMET00510 0.205 0.009 DBMET00869 | DBMET00510 | |
| 0.032 | 0.272 | 0.262 | Carbonic anhydrase VI inhibitor | 0.168 0.017 DBMET00510 0.262 0.008 DBMET00869 | DBMET00869 | |
| 0.007 | 0.248 | 0.057 | Prostaglandin D2 agonist | 0.057 0.006 DBMET00510 0.047 0.009 DBMET00869 | DBMET00510 | |
| 0.004 | 0.246 | 0.02 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.02 0.017 DBMET00869 | DBMET00869 | |
| 0.056 | 0.298 | 0.518 | Anesthetic general | 0.518 0.007 DBMET00510 0.516 0.007 DBMET00869 | DBMET00510 | |
| 0.036 | 0.278 | 0.234 | Chelator | 0.134 0.043 DBMET00510 0.234 0.019 DBMET00869 | DBMET00869 | |
| 0.035 | 0.278 | 0.084 | Protein kinase C zeta inhibitor | 0.084 0.077 DBMET00869 | DBMET00869 | |
| 0.049 | 0.293 | 0.336 | Angiogenesis stimulant | 0.318 0.043 DBMET00510 0.336 0.037 DBMET00869 | DBMET00869 | |
| 0.008 | 0.254 | 0.083 | Nicotinic acid receptor agonist | 0.083 0.006 DBMET00510 0.081 0.006 DBMET00869 | DBMET00510 | |
| 0.038 | 0.284 | 0.212 | Mucolytic | 0.203 0.013 DBMET00510 0.212 0.011 DBMET00869 | DBMET00869 | |
| 0.018 | 0.265 | 0.371 | Histidine decarboxylase inhibitor | 0.287 0.007 DBMET00510 0.371 0.004 DBMET00869 | DBMET00869 | |
| 0.019 | 0.268 | 0.065 | Aldosterone antagonist | 0.065 0.017 DBMET00510 | DBMET00510 | |
| 0.006 | 0.257 | 0.033 | Protocollagen prolyl hydroxylase inhibitor | 0.033 0.012 DBMET00510 0.033 0.012 DBMET00869 | DBMET00869 | |
| 0.022 | 0.274 | 0.078 | Transcription factor AP-1 inhibitor | 0.078 0.023 DBMET00510 0.075 0.026 DBMET00869 | DBMET00510 | |
| 0.005 | 0.257 | 0.057 | Farnesoid X receptor agonist | 0.057 0.011 DBMET00510 0.046 0.017 DBMET00869 | DBMET00510 | |
| 0.018 | 0.271 | 0.141 | Carbonic anhydrase VA inhibitor | 0.118 0.019 DBMET00510 0.141 0.013 DBMET00869 | DBMET00869 | |
| 0.005 | 0.261 | 0.061 | Estradiol 17 beta-dehydrogenase inhibitor | 0.061 0.019 DBMET00869 | DBMET00869 | |
| 0.03 | 0.286 | 0.121 | Caspase 7 inhibitor | 0.121 0.014 DBMET00510 0.104 0.025 DBMET00869 | DBMET00510 | |
| 0.012 | 0.269 | 0.093 | Carbonic anhydrase XIV inhibitor | 0.064 0.023 DBMET00510 0.093 0.013 DBMET00869 | DBMET00869 | |
| 0.004 | 0.262 | 0.052 | Carbonic anhydrase IV inhibitor | 0.052 0.024 DBMET00510 0.038 0.035 DBMET00869 | DBMET00510 | |
| 0.046 | 0.304 | 0.114 | D-Ala-D-Ala ligase inhibitor | 0.103 0.026 DBMET00510 0.114 0.017 DBMET00869 | DBMET00869 | |
| 0.051 | 0.31 | 0.143 | Interleukin 12 antagonist | 0.117 0.031 DBMET00510 0.143 0.015 DBMET00869 | DBMET00869 | |
| 0.007 | 0.268 | 0.049 | Catechol O-methyltransferase inhibitor | 0.03 0.028 DBMET00510 0.049 0.009 DBMET00869 | DBMET00869 | |
| 0.01 | 0.274 | 0.041 | RNA-directed RNA polymerase inhibitor | 0.038 0.02 DBMET00510 0.041 0.017 DBMET00869 | DBMET00869 | |
| 0.046 | 0.311 | 0.123 | Phosphodiesterase 6D inhibitor | 0.117 0.028 DBMET00510 0.123 0.022 DBMET00869 | DBMET00869 | |
| 0.063 | 0.33 | 0.149 | Interleukin 6 antagonist | 0.148 0.092 DBMET00510 0.149 0.091 DBMET00869 | DBMET00869 | |
| 0.006 | 0.276 | 0.036 | AMPA 2 receptor antagonist | 0.036 0.016 DBMET00510 | DBMET00510 | |
| 0.004 | 0.274 | 0.025 | Prostaglandin EP1 antagonist | 0.025 0.011 DBMET00510 | DBMET00510 | |
| 0.064 | 0.337 | 0.198 | Hemostatic | 0.198 0.033 DBMET00510 0.194 0.035 DBMET00869 | DBMET00510 | |
| 0.018 | 0.293 | 0.132 | Glucose-6-phosphate isomerase inhibitor | 0.132 0.003 DBMET00510 0.101 0.005 DBMET00869 | DBMET00510 | |
| 0.032 | 0.309 | 0.084 | Aminoacyl-tRNA synthetase inhibitor | 0.084 0.069 DBMET00510 0.084 0.07 DBMET00869 | DBMET00869 | |
| 0.065 | 0.344 | 0.173 | Tumour necrosis factor alpha release inhibitor | 0.173 0.132 DBMET00869 | DBMET00869 | |
| 0.035 | 0.314 | 0.194 | Estrogen receptor beta antagonist | 0.194 0.01 DBMET00869 | DBMET00869 | |
| 0.014 | 0.294 | 0.153 | Carbonic anhydrase V inhibitor | 0.124 0.02 DBMET00510 0.153 0.014 DBMET00869 | DBMET00869 | |
| 0.03 | 0.311 | 0.537 | Cystathionine beta-synthase inhibitor | 0.365 0.006 DBMET00510 0.537 0.003 DBMET00869 | DBMET00869 | |
| 0.012 | 0.293 | 0.04 | Estrogen-related receptor beta antagonist | 0.04 0.011 DBMET00869 | DBMET00869 | |
| 0.004 | 0.286 | 0.052 | Uridine phosphorylase inhibitor | 0.052 0.007 DBMET00510 0.047 0.009 DBMET00869 | DBMET00510 | |
| 0.011 | 0.297 | 0.04 | Retinoic acid alpha receptor agonist | 0.04 0.026 DBMET00510 | DBMET00510 | |
| 0.031 | 0.319 | 0.217 | UDP-glucose 4-epimerase inhibitor | 0.217 0.016 DBMET00510 0.174 0.022 DBMET00869 | DBMET00510 | |
| 0.044 | 0.341 | 0.135 | Acetylcholine release stimulant | 0.135 0.028 DBMET00510 0.118 0.052 DBMET00869 | DBMET00510 | |
| 0.049 | 0.349 | 0.36 | Interleukin antagonist | 0.31 0.045 DBMET00510 0.36 0.037 DBMET00869 | DBMET00869 | |
| 0.007 | 0.308 | 0.044 | Carbonic anhydrase VII inhibitor | 0.044 0.035 DBMET00869 | DBMET00869 | |
| 0.018 | 0.319 | 0.045 | Guanylate cyclase stimulant | 0.045 0.028 DBMET00510 | DBMET00510 | |
| 0.011 | 0.313 | 0.519 | Alcohol oxidase inhibitor | 0.446 0.004 DBMET00510 0.519 0.004 DBMET00869 | DBMET00869 | |
| 0.036 | 0.34 | 0.304 | Carbonic anhydrase III inhibitor | 0.22 0.013 DBMET00510 0.304 0.005 DBMET00869 | DBMET00869 | |
| 0.007 | 0.311 | 0.039 | Nicotinic acid receptor 2 agonist | 0.039 0.022 DBMET00510 0.037 0.023 DBMET00869 | DBMET00510 | |
| 0.033 | 0.338 | 0.292 | Protein-tyrosine phosphatase inhibitor | 0.286 0.022 DBMET00510 0.292 0.02 DBMET00869 | DBMET00869 | |
| 0.085 | 0.39 | 0.333 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.286 0.028 DBMET00510 0.333 0.015 DBMET00869 | DBMET00869 | |
| 0.005 | 0.31 | 0.129 | Estrogen agonist | 0.129 0.013 DBMET00869 | DBMET00869 | |
| 0.053 | 0.358 | 0.129 | Transcription factor STAT6 inhibitor | 0.129 0.046 DBMET00510 0.129 0.045 DBMET00869 | DBMET00869 | |
| 0.015 | 0.32 | 0.06 | Neuraminidase (influenza) inhibitor | 0.06 0.054 DBMET00869 | DBMET00869 | |
| 0.046 | 0.352 | 0.603 | Peroxidase inhibitor | 0.481 0.011 DBMET00510 0.603 0.004 DBMET00869 | DBMET00869 | |
| 0.082 | 0.389 | 0.39 | Gastrin inhibitor | 0.39 0.005 DBMET00510 0.341 0.013 DBMET00869 | DBMET00510 | |
| 0.011 | 0.32 | 0.159 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.103 0.016 DBMET00510 0.159 0.006 DBMET00869 | DBMET00869 | |
| 0.052 | 0.361 | 0.685 | Platelet antagonist | 0.685 0.005 DBMET00510 0.542 0.01 DBMET00869 | DBMET00510 | |
| 0.006 | 0.315 | 0.065 | Phosphorylase inhibitor | 0.065 0.022 DBMET00510 0.061 0.024 DBMET00869 | DBMET00510 | |
| 0.003 | 0.314 | 0.106 | Estrogen receptor beta agonist | 0.106 0.011 DBMET00869 | DBMET00869 | |
| 0.064 | 0.376 | 0.174 | 5 Hydroxytryptamine 1E antagonist | 0.174 0.161 DBMET00510 0.172 0.164 DBMET00869 | DBMET00510 | |
| 0.004 | 0.316 | 0.025 | Isoleucine-tRNA ligase inhibitor | 0.025 0.01 DBMET00510 0.022 0.017 DBMET00869 | DBMET00510 | |
| 0.036 | 0.349 | 0.141 | Microtubule formation inhibitor | 0.141 0.043 DBMET00510 0.131 0.05 DBMET00869 | DBMET00510 | |
| 0.004 | 0.318 | 0.037 | HCV NS5B polymerase inhibitor | 0.031 0.022 DBMET00510 0.037 0.017 DBMET00869 | DBMET00869 | |
| 0.041 | 0.358 | 0.426 | Cell adhesion inhibitor | 0.426 0.005 DBMET00510 0.288 0.011 DBMET00869 | DBMET00510 | |
| 0.004 | 0.323 | 0.03 | Endothelin receptor antagonist | 0.03 0.018 DBMET00510 | DBMET00510 | |
| 0.019 | 0.341 | 0.219 | Expectorant | 0.198 0.021 DBMET00510 0.219 0.017 DBMET00869 | DBMET00869 | |
| 0.018 | 0.34 | 0.075 | Glucose-6-phosphate translocase inhibitor | 0.058 0.026 DBMET00510 0.075 0.013 DBMET00869 | DBMET00869 | |
| 0.025 | 0.349 | 0.138 | Gastric antisecretory | 0.138 0.032 DBMET00510 0.127 0.038 DBMET00869 | DBMET00510 | |
| 0.016 | 0.343 | 0.166 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.121 0.029 DBMET00510 0.166 0.015 DBMET00869 | DBMET00869 | |
| 0.005 | 0.333 | 0.055 | Carnitine palmitoyltransferase inhibitor | 0.055 0.006 DBMET00510 0.041 0.015 DBMET00869 | DBMET00510 | |
| 0.038 | 0.368 | 0.083 | Thioredoxin reductase inhibitor | 0.083 0.054 DBMET00869 | DBMET00869 | |
| 0.083 | 0.417 | 0.478 | Vasodilator, peripheral | 0.474 0.034 DBMET00510 0.478 0.033 DBMET00869 | DBMET00869 | |
| 0.004 | 0.34 | 0.092 | Leukotriene A4 hydrolase inhibitor | 0.092 0.007 DBMET00510 0.065 0.013 DBMET00869 | DBMET00510 | |
| 0.023 | 0.359 | 0.153 | Alkylator | 0.15 0.047 DBMET00510 0.153 0.045 DBMET00869 | DBMET00869 | |
| 0.019 | 0.358 | 0.054 | CXC chemokine 1 receptor antagonist | 0.054 0.03 DBMET00869 | DBMET00869 | |
| 0.001 | 0.341 | 0.015 | Carbonic anhydrase XI inhibitor | 0.015 0.006 DBMET00510 | DBMET00510 | |
| 0.034 | 0.374 | 0.189 | NADH dehydrogenase inhibitor | 0.189 0.011 DBMET00510 0.151 0.017 DBMET00869 | DBMET00510 | |
| 0.003 | 0.344 | 0.019 | Retinoic acid alpha receptor antagonist | 0.019 0.015 DBMET00510 | DBMET00510 | |
| 0.035 | 0.378 | 0.145 | Antibacterial (Helicobacter pylori) | 0.144 0.051 DBMET00510 0.145 0.05 DBMET00869 | DBMET00869 | |
| 0.084 | 0.429 | 0.241 | RNA-directed DNA polymerase inhibitor | 0.241 0.055 DBMET00510 0.23 0.064 DBMET00869 | DBMET00510 | |
| 0.034 | 0.382 | 0.304 | DNA polymerase I inhibitor | 0.304 0.011 DBMET00510 0.3 0.011 DBMET00869 | DBMET00510 | |
| 0.084 | 0.436 | 0.308 | Antibacterial | 0.282 0.149 DBMET00510 0.308 0.129 DBMET00869 | DBMET00869 | |
| 0.027 | 0.379 | 0.136 | Alkaline phosphatase inhibitor | 0.136 0.07 DBMET00869 | DBMET00869 | |
| 0.007 | 0.36 | 0.044 | NMDA 2D receptor antagonist | 0.044 0.009 DBMET00510 0.032 0.014 DBMET00869 | DBMET00510 | |
| 0.012 | 0.367 | 0.096 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.096 0.015 DBMET00510 0.061 0.033 DBMET00869 | DBMET00510 | |
| 0.017 | 0.373 | 0.223 | Carbonic anhydrase XIII inhibitor | 0.162 0.019 DBMET00510 0.223 0.011 DBMET00869 | DBMET00869 | |
| 0.004 | 0.364 | 0.051 | Carnitine palmitoyltransferase 1 inhibitor | 0.051 0.007 DBMET00510 0.039 0.017 DBMET00869 | DBMET00510 | |
| 0.01 | 0.371 | 0.051 | p53 inhibitor | 0.051 0.014 DBMET00510 | DBMET00510 | |
| 0.003 | 0.364 | 0.103 | Kynurenine 3 monooxygenase inhibitor | 0.103 0.004 DBMET00510 0.05 0.007 DBMET00869 | DBMET00510 | |
| 0.026 | 0.39 | 0.139 | Cyclooxygenase 1 inhibitor | 0.139 0.064 DBMET00869 | DBMET00869 | |
| 0.005 | 0.373 | 0.064 | Guanylate cyclase inhibitor | 0.064 0.009 DBMET00510 0.053 0.018 DBMET00869 | DBMET00510 | |
| 0.01 | 0.381 | 0.042 | Glutamate (mGluR4) agonist | 0.042 0.014 DBMET00510 0.033 0.026 DBMET00869 | DBMET00510 | |
| 0.082 | 0.453 | 0.443 | Sodium/bile acid cotransporter inhibitor | 0.441 0.009 DBMET00510 0.443 0.008 DBMET00869 | DBMET00869 | |
| 0.006 | 0.386 | 0.022 | Retinoic acid gamma receptor agonist | 0.022 0.017 DBMET00510 | DBMET00510 | |
| 0.024 | 0.407 | 0.273 | Keratolytic | 0.202 0.008 DBMET00510 0.273 0.004 DBMET00869 | DBMET00869 | |
| 0.045 | 0.43 | 0.278 | Vasodilator | 0.249 0.07 DBMET00510 0.278 0.056 DBMET00869 | DBMET00869 | |
| 0.038 | 0.427 | 0.231 | Farnesoid X receptor antagonist | 0.174 0.032 DBMET00510 0.231 0.015 DBMET00869 | DBMET00869 | |
| 0.019 | 0.419 | 0.206 | Mediator release inhibitor | 0.169 0.022 DBMET00510 0.206 0.014 DBMET00869 | DBMET00869 | |
| 0.04 | 0.441 | 0.741 | Aldehyde oxidase inhibitor | 0.637 0.014 DBMET00510 0.741 0.006 DBMET00869 | DBMET00869 | |
| 0.05 | 0.456 | 0.332 | Thyroid hormone beta antagonist | 0.293 0.092 DBMET00510 0.332 0.075 DBMET00869 | DBMET00869 | |
| 0.027 | 0.434 | 0.126 | Thioredoxin inhibitor | 0.105 0.042 DBMET00510 0.126 0.027 DBMET00869 | DBMET00869 | |
| 0.023 | 0.431 | 0.207 | Uric acid excretion stimulant | 0.207 0.012 DBMET00510 0.205 0.012 DBMET00869 | DBMET00510 | |
| 0.017 | 0.426 | 0.049 | Topoisomerase II beta inhibitor | 0.049 0.034 DBMET00869 | DBMET00869 | |
| 0.004 | 0.413 | 0.021 | Purinergic P2Y12 antagonist | 0.021 0.017 DBMET00510 | DBMET00510 | |
| 0.027 | 0.437 | 0.114 | Cyclooxygenase inhibitor | 0.114 0.107 DBMET00869 | DBMET00869 | |
| 0.047 | 0.474 | 0.251 | NOS3 expression enhancer | 0.159 0.064 DBMET00510 0.251 0.026 DBMET00869 | DBMET00869 | |
| 0.003 | 0.438 | 0.043 | Prostacyclin agonist | 0.043 0.005 DBMET00510 0.025 0.007 DBMET00869 | DBMET00510 | |
| 0.056 | 0.496 | 0.553 | Hypoglycemic | 0.553 0.011 DBMET00510 0.55 0.011 DBMET00869 | DBMET00510 | |
| 0.014 | 0.454 | 0.073 | Topoisomerase II alpha inhibitor | 0.073 0.059 DBMET00869 | DBMET00869 | |
| 0.023 | 0.463 | 0.068 | Adenine nucleotide translocase inhibitor | 0.059 0.03 DBMET00510 0.068 0.017 DBMET00869 | DBMET00869 | |
| 0.045 | 0.487 | 0.289 | Cyclic AMP phosphodiesterase inhibitor | 0.284 0.048 DBMET00510 0.289 0.046 DBMET00869 | DBMET00869 | |
| 0.069 | 0.514 | 0.239 | Catenin beta inhibitor | 0.235 0.014 DBMET00510 0.239 0.013 DBMET00869 | DBMET00869 | |
| 0.005 | 0.454 | 0.148 | Aldose reductase inhibitor | 0.133 0.012 DBMET00510 0.148 0.011 DBMET00869 | DBMET00869 | |
| 0.023 | 0.474 | 0.1 | Breast cancer-resistant protein inhibitor | 0.1 0.055 DBMET00869 | DBMET00869 | |
| 0.022 | 0.477 | 0.123 | Multidrug resistance-associated protein 1 inhibitor | 0.115 0.054 DBMET00510 0.123 0.044 DBMET00869 | DBMET00869 | |
| 0.007 | 0.466 | 0.083 | Xanthine dehydrogenase inhibitor | 0.055 0.042 DBMET00510 0.083 0.023 DBMET00869 | DBMET00869 | |
| 0.032 | 0.492 | 0.505 | Platelet aggregation inhibitor | 0.505 0.009 DBMET00510 0.355 0.025 DBMET00869 | DBMET00510 | |
| 0.015 | 0.476 | 0.161 | M18 aspartyl aminopeptidase inhibitor | 0.161 0.047 DBMET00869 | DBMET00869 | |
| 0.02 | 0.489 | 0.113 | Beta glucuronidase inhibitor | 0.113 0.053 DBMET00869 | DBMET00869 | |
| 0.03 | 0.5 | 0.201 | NADPH oxidase inhibitor | 0.13 0.071 DBMET00510 0.201 0.034 DBMET00869 | DBMET00869 | |
| 0.025 | 0.509 | 0.093 | MAP kinase kinase 7 inhibitor | 0.084 0.036 DBMET00510 0.093 0.02 DBMET00869 | DBMET00869 | |
| 0.041 | 0.528 | 0.131 | Tumour necrosis factor antagonist | 0.131 0.125 DBMET00869 | DBMET00869 | |
| 0.016 | 0.504 | 0.074 | Ryanodine receptor antagonist | 0.071 0.017 DBMET00510 0.074 0.013 DBMET00869 | DBMET00869 | |
| 0.017 | 0.506 | 0.085 | ATPase (Vacuolar H+) inhibitor | 0.085 0.067 DBMET00869 | DBMET00869 | |
| 0.07 | 0.562 | 0.368 | Apoptosis agonist | 0.368 0.129 DBMET00869 | DBMET00869 | |
| 0.033 | 0.526 | 0.322 | Platelet adhesion inhibitor | 0.322 0.027 DBMET00510 0.318 0.028 DBMET00869 | DBMET00510 | |
| 0.006 | 0.509 | 0.118 | HIV-1 integrase (3'-Processing) inhibitor | 0.055 0.054 DBMET00510 0.118 0.02 DBMET00869 | DBMET00869 | |
| 0.066 | 0.571 | 0.254 | Caspase 3 stimulant | 0.254 0.109 DBMET00869 | DBMET00869 | |
| 0.039 | 0.548 | 0.484 | 15-Lipoxygenase inhibitor | 0.363 0.092 DBMET00510 0.484 0.044 DBMET00869 | DBMET00869 | |
| 0.03 | 0.543 | 0.31 | DNA synthesis inhibitor | 0.31 0.04 DBMET00510 0.275 0.053 DBMET00869 | DBMET00510 | |
| 0.014 | 0.529 | 0.203 | Mcl-1 antagonist | 0.148 0.091 DBMET00510 0.203 0.054 DBMET00869 | DBMET00869 | |
| 0.035 | 0.554 | 0.189 | Hexokinase inhibitor | 0.181 0.048 DBMET00510 0.189 0.043 DBMET00869 | DBMET00869 | |
| 0.026 | 0.549 | 0.179 | Amyloid beta precursor protein antagonist | 0.141 0.112 DBMET00510 0.179 0.073 DBMET00869 | DBMET00869 | |
| 0.03 | 0.553 | 0.245 | Nitric oxide antagonist | 0.173 0.08 DBMET00510 0.245 0.053 DBMET00869 | DBMET00869 | |
| 0.008 | 0.532 | 0.116 | CDC25B inhibitor | 0.112 0.013 DBMET00510 0.116 0.012 DBMET00869 | DBMET00869 | |
| 0.02 | 0.544 | 0.2 | Mannose-6-phosphate isomerase inhibitor | 0.2 0.031 DBMET00510 0.189 0.037 DBMET00869 | DBMET00510 | |
| 0.022 | 0.549 | 0.466 | Free radical scavenger | 0.281 0.057 DBMET00510 0.466 0.02 DBMET00869 | DBMET00869 | |
| 0.005 | 0.544 | 0.036 | Caspase 2 inhibitor | 0.036 0.018 DBMET00510 | DBMET00510 | |
| 0.026 | 0.566 | 0.108 | Interleukin 5 antagonist | 0.107 0.034 DBMET00510 0.108 0.033 DBMET00869 | DBMET00869 | |
| 0.019 | 0.564 | 0.177 | Xanthine oxidase inhibitor | 0.111 0.052 DBMET00510 0.177 0.025 DBMET00869 | DBMET00869 | |
| 0.004 | 0.549 | 0.043 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.043 0.019 DBMET00869 | DBMET00869 | |
| 0.012 | 0.557 | 0.058 | Carnitine palmitoyltransferase 1B inhibitor | 0.058 0.019 DBMET00510 | DBMET00510 | |
| 0.015 | 0.562 | 0.29 | Lipid peroxidase inhibitor | 0.179 0.051 DBMET00510 0.29 0.02 DBMET00869 | DBMET00869 | |
| 0.018 | 0.571 | 0.212 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.171 0.12 DBMET00510 0.212 0.093 DBMET00869 | DBMET00869 | |
| 0.025 | 0.583 | 0.459 | Antioxidant | 0.289 0.066 DBMET00510 0.459 0.025 DBMET00869 | DBMET00869 | |
| 0.008 | 0.581 | 0.154 | CDC25A inhibitor | 0.154 0.012 DBMET00510 0.15 0.013 DBMET00869 | DBMET00510 | |
| 0.009 | 0.583 | 0.181 | M17 leucyl aminopeptidase inhibitor | 0.181 0.04 DBMET00510 0.16 0.05 DBMET00869 | DBMET00510 | |
| 0.022 | 0.603 | 0.333 | DNA methylase inhibitor | 0.305 0.026 DBMET00510 0.333 0.02 DBMET00869 | DBMET00869 | |
| 0.019 | 0.608 | 0.323 | DNA methyltransferase I inhibitor | 0.295 0.028 DBMET00510 0.323 0.019 DBMET00869 | DBMET00869 | |
| 0.009 | 0.615 | 0.098 | Topoisomerase II inhibitor | 0.098 0.089 DBMET00869 | DBMET00869 | |
| 0.047 | 0.662 | 0.274 | Lipocortins synthesis antagonist | 0.274 0.027 DBMET00510 0.216 0.047 DBMET00869 | DBMET00510 | |
| 0.013 | 0.64 | 0.26 | Dual specificity phosphatase 3 inhibitor | 0.23 0.047 DBMET00510 0.26 0.037 DBMET00869 | DBMET00869 | |
| 0.005 | 0.634 | 0.108 | HIV-1 integrase (Strand Transfer) inhibitor | 0.057 0.043 DBMET00510 0.108 0.02 DBMET00869 | DBMET00869 | |
| 0.023 | 0.656 | 0.055 | Lipocortins synthesis agonist | 0.055 0.048 DBMET00510 0.055 0.048 DBMET00869 | DBMET00869 | |
| 0.027 | 0.662 | 0.085 | Transcription factor NF kappa B stimulant | 0.085 0.059 DBMET00510 0.085 0.059 DBMET00869 | DBMET00869 | |
| 0.03 | 0.683 | 0.242 | Hepatoprotectant | 0.217 0.056 DBMET00510 0.242 0.046 DBMET00869 | DBMET00869 | |
| 0.023 | 0.676 | 0.296 | Hypoxia-inducible factor 1 alpha inhibitor | 0.227 0.122 DBMET00510 0.296 0.067 DBMET00869 | DBMET00869 | |
| 0.009 | 0.669 | 0.287 | Pyruvate kinase inhibitor | 0.191 0.086 DBMET00510 0.287 0.051 DBMET00869 | DBMET00869 | |
| 0.013 | 0.688 | 0.286 | Dual specificity phosphatase inhibitor | 0.253 0.037 DBMET00510 0.286 0.031 DBMET00869 | DBMET00869 | |
| 0.005 | 0.712 | 0.114 | HIV-1 integrase inhibitor | 0.081 0.037 DBMET00510 0.114 0.018 DBMET00869 | DBMET00869 | |
| 0.015 | 0.819 | 0.147 | Toll-Like receptor 4 antagonist | 0.133 0.032 DBMET00510 0.147 0.023 DBMET00869 | DBMET00869 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |